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Mallin, Lainey Jo.M.S., Department of Chemistry, Wright State University, 2015. 
Proxy-PET building blocks as a Design Element for Library Synthesis 
 
In exploring radioligands for positron emission tomography (PET) imaging, it is not 
unusual to synthesize a library of compounds around some targeting scaffold, screen for 
optimal binding to a relevant diagnostic cellular target, remove some portion of 
optimized molecule so as to append the requisite reporter group, and then re-evaluate. To 
this end, the use of “click labeling” in radiochemistry is proving an increasingly attractive 
means of conjugating a 18F-reporter group, wherein the targeting scaffold bearing a 
terminal alkyne is allowed to react with a 2-[18F]-fluoroethylazide to forge a linkage as a 
1,2,3-triazole substituent. Since the triazole linked prosthetic group is a necessary portion 
of the eventual PET imaging agent, it was envisioned that building blocks possessing a 
“cold” version of the triazole linked fluoroethyl group might be incorporated early in the 
synthetic plan as a crucial library design element.  The analog so designed and exhibiting 
optimal binding would, in a radioactive form, represent the eventual PET imaging agent. 
To that end, we have prepared such building blocks from the copper(I) catalyzed click 
reaction between sodium azide, 2-fluoroethyl tosylate (or benzyl bromide) and 
propargylic alcohol. Conversion of the alcohol building block to the corresponding 
aldehyde could be effected using MnO2, which was appended to a scaffold of interest 
using an aldol condensation. Conversion to the bromomethyl derivative was achieved 






usefulness of such building blocks has been demonstrated in the case of synthesizing and 
evaluating small libraries around the oxindole and isatin privileged scaffolds. Subsequent 
manipulations led to the ultimate target structure, being a benzylidene oxindole bearing a 
N-triazole linked moiety. For instance, whereas the bromomethyl triazole can be utilized 
for N-alkylations of the aforementioned scaffolds towards targets of importance in 
Alzheimer’s disease (such as tau proteins, caspase-3, cdk5, and AChE), the aldehyde can 
be employed in aldol reactions. The introduction of such proxy-PET moieties at an early 
stage of the library synthesis has an added benefit of avoiding the presence of copper 
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 The year was 1906 and Auguste D. was losing her mind.  Dr. Alois Alzheimer 
observed this 51 year old woman who was suffering from progressive memory loss as 
well as other neurological disturbances such as unwarranted jealousy towards her 
husband and delusions that someone was trying to kill her.  Upon Auguste's death, Dr. 
Alzheimer studied her brain by using silver staining.  He identified two types of senile 
plaques, namely neuritic plaques (amyloid-β proteins) and neurofibrillary tangles (tau-
proteins).1 Dr. Alzheimer presented his findings and clinical characteristics of the disease 
at a conference in 1906.2 
 Alzheimer's disease (AD) is a type of dementia that slowly destroys brain 
function and leads to cognitive decline as well as behavioral and psychiatric disorders.  
Dementia is an umbrella term which describes any disease that irreversibly damages 
nerve cells in the brain resulting in a decline in mental ability severe enough to interfere 
with performing the activities associated with daily life.3 Main pathological features of 
the disease include the co-occurrence of plaques and tangles, loss of connections between 
neurons, and finally neuronal death and brain shrinkage.4 
 Over 100 years has passed since Dr. Alzheimer disclosed his discovery of a new 
type of neurodegenerative disease later to be named after its discoverer.1,2,5  Little did Dr. 






epidemic in the 21st century. Between 1906, when Alzheimer's disease was first 
documented, and 2006, one hundred years later, human life expectancy in the United 
States increased from 48.5 years to 78.5 years.6,7 Considering the fact that the principle 
risk factor for Alzheimer's disease is age,8 the prevalence of this disease has risen 
dramatically and will continue to do so as life expectancy continues to increase.  At 
present, there are no cures, treatments, or drugs that can so much as slow the progression 
of Alzheimer's disease, nor are there means of diagnosing malady. 
 Amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) are the hallmarks 
of the AD, however with no approved imaging agent to visualize a diagnostic protein in 
vivo, it is very difficult to accurately determine pre-mortem if a patient has AD especially 
since the symptoms characteristics of AD are similar to those present in other dementias 
associated with aging.9,10  While there are imaging agents used in AD research, such 
agents target proteins in the brain which do not necessarily correlate well with the 
cognitive decline observed. 
 Symptoms of Alzheimer's disease include memory impairment, decline in 
language skills and decision making, behavioral changes, loss of ability to recognize 
family, and ultimately loss of self.11  Such a list of pathological symptoms does come 
near to describing the devastation and anguish experienced by the patient and their 
family.  Ronch said it best when he stated: "but worse, the loss of self happens before the 
very eyes of the person whose self is vanishing.  The basis of unique personal identity 






 Based on Dr. Alzheimer’s findings and another 80+ years of research on the post-
mortem brains of people who exhibited symptoms similar to those of Auguste D., two 
main hypotheses have been developed concerning the cause of the disease. The first, the 
so-called “amyloid cascade hypothesis” was developed in 1992 by Hardy and Higgins,13 
who implicated the Aβ plaques as being the causative agent in AD pathology.13  The 
plaques are the result of the sequential cleavage of the amyloid precursor protein (APP) 
by β-secretase and ɣ-secretase enzymes which result in the generation of amyloid protein 
fragments of 36 to 43 amino acids in length. Of these monomeric species produced, the 
A42 fragment is the most toxic and most prone to aggregation while A40 is the most 
prevalent.14,15 As illustrated by Figure 1; the enzyme β-secretase cleaves the protein in 
the extracellular area and then ɣ-secretase cleaves the protein via intra-membrane 
proteolysis resulting in formation of the fragments.15  Another secretase, α-secretase is 
also involved in the cleavage of APP, however if α-secretase cleaves the protein then no 
toxic fragments will be formed.15 In any event, the monomers (especially A42) then 
aggregate to form the Aβ plaques thought to initiate the cascade of events leading to 
AD.16 At the time, and until very recently, it was thought that since these plaques were 
likely the cause of AD, therapeutic strategies aimed at preventing the formation of and/or 








Figure 1: APP cleavage by secretases 
 Now, after several drugs capable of clearing Aβ plaques have been developed and 
studied, we are beginning to suspect that ridding the brain of these plaques may have 
little or no effect on the progression of the disease.17,18 Three out of five drugs that have 
been developed (none of which have been approved by FDA) to reduce or clear Aβ 
plaques are shown.  Flurizan19 (1)and Semagacestat20 (2) reduce Aβ burden via ɣ-
secretase modulation (Flurizan)21 or complete inhibition (Semagacestat).  Phenserine22 
(3) works to modulate Aβ generation by non-competitively inhibiting 







Two other drugs not shown, Bapineuzumab23 and Solanezumab,24 are antibodies that 
work by binding to the plaques in the brain and activating phagocytosis.  When these 
drugs were tested on mice, results were very promising showing that plaques were 
cleared and symptoms of the disease disappeared causing the mice to seem as though 
they were not diseased anymore.25-27 Unfortunately, all of these drugs described had no 
effect on the progression of AD in humans and in some cases caused negative side effects 
to the patients.22, 28-31 Also, research has shown that the amount of Aβ plaque in the brain 
has no correlation with the degree of cognitive impairment; additionally, plaques can be 
present in the brain without that person displaying any symptoms of AD.17,32,33 Hardy did 
state in 1994 that “the amyloid cascade hypothesis is just a skeletal outline/framework 
not meant to imply that genetics, APP metabolism, and beta-amyloid neurotoxicity are 
the only important topics of research in AD or that amyloid deposition is the only cause 
of dementia”.34 He stated that the hypothesis only implied that the disease process would 
become more biochemically complex with the onset of the cascade.34  Perhaps his 
statements were meant to warn researchers to not to put all their eggs in one basket and to 
continue exploring the complexity of AD; however there is no question that most of the 
research and funding for AD over the past 20 years has been aimed at targets 
implemented with this hypothesis.   
 Another hypothesis gaining momentum is known as the tau hypothesis. Since 
2004, more attention has been given to this hypothesis which was coined by Trojanowski 
in 2005,35-38 and suggests that AD pathology starts with hyperphosphorylation of the tau 
protein, which in turn, leads to NFT’s and finally the other pathological characteristics of 






Dr. Alzheimer in 1906, however the protein involved in forming these tangles was not 
identified as hyperphosphorylated tau until 1986.42  In contrast to amyloid plaques, the 
amount of neurofibrillary lesions found in the brain does correlate better with the severity 
or progression of the disease.43  Research showing that tau pathology appears in certain 
areas of the brain decades before Aβ plaques, as well as before signs of dementia surface; 
supports the tau hypothesis.44,55 Increased levels of NFT’s in the brain46,47 and in 
cerebrospinal fluid48 are positively correlated to reduced scores on cognitive tests17,46 
whereas appearance of Aβ plaques (as mentioned before) do not necessarily mean a 
person will ever develop AD.49 
 In 2011, the Alzheimer’s Association, the National Institute on Aging, and the 
U.S. National Institute of Health jointly issued new criteria and guidelines to diagnose 
AD.  Diagnosis is now based on three clinical stages; preclinical AD, mild cognitive 
impairment, and dementia caused by AD.  Preclinical AD doesn't have any detectable 
symptoms but there is thought to be changes in biomarker levels, however there is no 
definite biomarker tracer as of yet so this stage cannot yet be clinically identified pre-
mortem.  The second stage of AD is mild cognitive impairment which causes symptoms 
in the patient such as some memory loss, however, these symptoms are ones that do not 
affect the everyday life of the patient.  Dementia caused by AD, the third stage, is where 
symptoms do interfere with everyday life and those affected become unable to care for 
themselves. When AD is diagnosed, there are only a couple of options for the patient:  
they can choose to take no action against the disease or they can take palliative 






 As of 2015, there are five medications that have been approved by the FDA as 
palliative treatments for the symptoms caused by AD.  These drugs vary in effectiveness 
and have shown only marginal benefits when found effective.50 Four of the drugs are 
acetylcholinesterase (AChE) inhibitors and one is an N-methyl-D-aspartate (NMDA) 
receptor antagonist.51 AChE inhibitors work by slowing down the process that breaks 
down acetylcholine (Ach), a key neurotransmitter.52 NMDA receptor antagonists work by 
regulating the activity of glutamate, an important neurotransmitter that regulates the 
calcium uptake necessary for proper brain functioning.53 However, too much of a good 
thing can be bad.  Excess glutamate can be released from damaged neuronal cells leading 
to overexposure to calcium and expedited cell damage. These drugs can help AD patients 
manage their symptoms, however they are not disease specific and do not always work.51 
 Other drug options that are being explored are ɣ-secretase inhibitors, β-secretase 
inhibitors, and α-secretase inhibitors.  ɣ-Secretases are involved with a number of critical 
processes within the human body and because of that, this protein must be modulated and 
not completely inhibited; a challenge which has significantly limited progress in this 
area.54 One idea would be to block the ATP binding site on ɣ-secretase that modulates 
APP processing.55,56Netzer et al.56 and Fraering et al.55 describe how modulating the ATP 
binding site can reduce Aβ burden.  Nonsteroidal anti-inflammatory drugs (NSAID’s) 
which allosterically modulate ɣ-secretase so as to produce more of the less toxic 40 
amino acid fragments versus 42 fragments might also be an option.57,58 A better option 
would be a drug that interferes with β-secretase because it is not involved in any other 
physiological processes. Human APP transgenic mice that have β-secretase genetically 






secretase shut off it cannot cleave APP thus no toxic monomers will be formed which 
means that no plaques will form.  Alternatively, α-secretase processes the APP at a point 
that prevents the more toxic fragments from being produced, which means up-regulation 
of this secretase might be a target for intervention.60 Immune mechanisms to clear 
plaques in the brain associated with AD could help also, however as mentioned earlier, 
five drugs that do this have already failed, so it does not seem like a very promising 
avenue.18 Small molecules that can disrupt aggregation might be a viable option as well.61 
One such small molecule is Alzhemed (4), (shown in neutral form) also known as 3-
amino-1-propanesulfonic acid or 3-aminopropylsulfonic acid.  In vitro studies showed 
preferential binding to soluble Athus inhibiting Aβ aggregation.  Additionally, 
treatment of mice with Alzhemed resulted in reduction of A  in the brain.62 
Unfortunately, in August of 2007 the FDA deemed the stage 3 clinical trials 
inconclusive.63 
 
 Non-pharmaceutical treatments such as physical and reminiscence therapy have 
also been studied.  These therapies do not alter the progression of the disease and in the 
few studies on effectiveness of these types of treatments; they did not seem to help the 
patient all that much.64 The spice curcumin (5) is often used in Indian food to flavor and 
give color.  It has been proposed that curcumin may be a risk reducer for developing AD 
since it is thought to have neuronal protective properties.65 Caffeine (6) is another natural 






symptoms appear. There have been a couple of studies that involve mice predisposed to 
develop AD and when given the equivalent of 5 cups of coffee a day (for a human) they 
take longer to exhibit AD symptoms.  Additionally, when the mice are already exhibiting 
symptoms of the disease they show improved brain function after they are given 
caffeine.66,67 
  
 As alluded to earlier, an imaging agent for Alzheimer’s is desperately needed.  
Currently, AD can only be diagnosed post-mortem which is not much help except to give 
an official cause of death in some cases when an autopsy of an elderly individual is 
conducted. A conclusive imaging agent could not only distinguish between the various 
dementias associated with aging to provide for better diagnosis, but it could also help 
monitor the progression of patients undergoing treatments as they are developed.68 Out of 
the five Aβ positron emission tomography (PET) imaging agents (vide infra) that have 
had human trials, three have been approved by the FDA. All of the imaging agents 
developed to date have been based on the structures of highly fluorescent dyes: Congo 
Red (7), Chrysamine G (8), and Thioflavin T (9) that are used to detect A  plaques and 
NFTs in the brain post-mortem.70 Amyvid (10) (a.k.a. Florbentapir) was the first to be 
approved by the FDA in 2012, followed by Vizamyl (12) (a.k.a. Flutemetamol) in 2013, 
and finally, Neuraceq (11) (a.k.a. Florbetaben) in 2014.69Amyvid and Neuraceq have 






Thioflavin T. Each of these agents has been shown to be effective for the non-invasive 
imagingof amyloid plaques in the pre-mortem brain. Despite this progress, in 2012 the 
Human Amyloid Imaging Conference suggested that appearance of amyloid plaques in a 





 Seven molecules, belonging to three classes of compounds, have recently been 
developed as possible tau PET imaging agents. Of this group, [18F]THK523 (13), 
[18F]THK5105 (14), and [18F]THK5117 (15) are quinoline derivatives, [18F]T807 (16) 
and [18F]T808 (17) are pyrimidine derivatives, and [11C]PBB3 (18) and [18F]FDDNP (19) 







in vivo and while it was shown to target tau it also targeted Aβ which is undesirable.72  
Additionally, [18F]THK-523 (13) failed to visualize NFTs clearly73 and [11C]PBB3 (18) is 
tagged with a radioactive carbon which is not favored when it comes to developing a 
PET-imaging agent.74 In-vivo human studies of [11C]PBB3,74 [18F]T807,75 (16) and 
[18F]THK510576 (14) showed promising results, however, an imaging agent for tau has 









 If AD continues to progress at its current rate and we do not develop a disease 
altering medication, it will be devastating for not only the 13.8 million people projected 
to have the disease by 2050 but also their families and the economy.3A consensus about 
what needs to be done about this epidemic needs to be reached. Broadly speaking, either 
multiple drugs with different modes of action, or a single drug that has multiple 
functions, will be required for individualized regimens which means we, as a nation, have 
a long way to go considering what is currently available.  
 While the amyloid cascade and tau hypotheses offer insight to the pathology and 
possible causes of AD, they do not individually explain the full complexity of AD.  In 
order to move forward with drug discovery efforts for this multi- factorial disease77 there 
is growing consensus that the paradigm of the “one-compound-various targets”78,79 must 
be employed.  Though the etiology of AD is not completely known, experts do know of 
several components that contribute to the disease, including Aβ deposits, tau protein 
aggregation, oxidative stress, and a decrease in ACh levels.  Other “players” involved in 
AD development include, but are not on any terms limited to, Ca2+ imbalance, excess of 







 Development of drugs such as Bapineuzumab, Phenserine, Flurizan, 
Semagacestat, and Solanezumab which help clear A  plaques out of the brain (outlined 
earlier) and tacrine, donepezil, rivastigmine, and galantamine which inhibit AChE to 
increase Ach,79 have not been able to even alter or slow progression of the disease.  For a 
review of all drugs (failed and approved by FDA) developed for AD prior to 2010 refer to 
the article by Sabbagh.81Noteworthy is the fact that the development of these drugs over 
the past decades has been based on the “one target one compound” paradigm which has 
been very successful in the past for some diseases. However, with a disease as complex 
as AD this paradigm has not been, and will not likely be successful.80 This disease seems 
to be very efficient at finding a window to proceed through when a door is closed in its 
path.  The complexity of this disease, as well as a century old history of failed single 
target drugs, warrants the progression into developing a drug that can target more than 
one proposed cause of disease at a time.  Most efforts along these lines have been based 
upon coupling drugs which inhibit acetycholinestease along with targeting some other 
component of the disease.  Memoquin (20) is an example of a multitarget lead drug that 
has been tested and shown to be effective at targeting multiple factors believed to lead to 
Alzheimer’s disease, including AChE inhibition, altering expression and deposition of 
A  and altering hyperphosphorylation and deposition of tau.82,83 Recently, a dual 
inhibition lead compound was disclosed as being capable of inhibiting Dyrk1A (a major 
tau kinase) and formation of A  plaques.84,85 Although such multitarget drugs are at an 
early stage of development, it is clear that this approach is becoming more widespread. 






polypharmacology) read the article by Rastelli86 or for a review that specifically relates to 
AD read the article by León.80 
 
 The Ketcha research group at WSU is exploring the idea of polypharmacology by 
designing molecules to inhibit caspase-3 and acetylcholinesterase or caspase-3 and 
cyclin-dependent kinase 5 (cdk5).  These biological targets have the ability to affect 
gamma secretase activating protein (GSAP) and the Golgi apparatus which have been 
shown to be involved in the development of Alzheimer’s disease. Greengard showed in 
2007 that arylidene oxindoles, specifically IC261 [(E)-3-(2,4,6-
trimethoxybenzylidene)indolin-2-one] (21), could reduce endogenous Aβ production by 
possibly inhibiting casein kinase 1 (CK1).87 However, N-alkylation, which is known to 
nullify activity against kinases, of a similar molecule, BSc3927 (22), still showed A-
inhibitory activity therefore showing that CK1 was likely not involved.88 
  GSAP was discovered to be capable of affecting Aβ production without affecting 
other important biologic pathways such as the Notch signaling pathway which is 
important for neuronal cell communication.  GSAP interacts with amyloid precursor 
protein c-terminal fragment (APP-CTF).  This interaction directs gamma secretase to 






inhibiting GSAP does not directly inhibit gamma secretase which has other biologic 
function; it is considered a good target for possible Alzheimer’s disease treatment.89 
Almost 15 years ago was the first time caspase-3 was shown to have a link to the 
development of Alzheimer’s disease by causing neuronal cell death via apoptosis;90 
however in 2014 Practico linked caspase-3 to GSAP.91 He discovered that GSAP must be 
activated by caspase-3 in turn showing that caspase-3 may be a good enzyme target to 
lower A  plaque formation.91 
 
  
 Cyclin dependent kinase (cdk5) is also a target of interest because of the 
implications that it is linked to the phosphorylation of tau protein and GRASP65 which is 
involved in the stacking of the Golgi apparatus.92 Cdk5 has also been implicated in 
causing neuronal apoptosis.93 In 1992, it was determined that cdk5 was involved in the 
hyperphosphorylation of tau94 but only recently was it also linked to fragmentation of the 
Golgi apparatus.92  Furthermore, it is thought Golgi fragmentation can lead to the 
development of AD.92,95 With a disease as complex as Alzheimer’s disease nothing can 






lowering Aβ plaque production by inhibiting caspase-3 and/or cdk5 utilizing compounds 
designed around the privileged heterocyclic scaffolds of oxindole and isatin. 
 Privileged scaffolds are useful starting points for drug discovery efforts because 
by definition they are capable of binding as ligands to multiple unrelated receptors. 
Oxindole (24) and isatin (23) are considered privileged scaffolds96 because of their broad 
range of biological activities and the multiple sites for diversification that they offer.  In 
relation to Alzheimer’s disease it is important to note that an oxindole derivative, 25, has 
been shown to have binding affinity for tau protein.97  Other oxindole derivatives have 
been shown to be protein kinase inhibitors98 which have been implicated as being 
involved with AD pathology.93  Additionally, compounds containing the isatin privileged 
scaffold have been used to inhibit caspase-3, also known as cysteine aspartyl-specific 









 Based on the usefulness and success of isatin (23) and oxindole (24) in 
pharmaceuticals, linking a radioactive tag to such scaffolds could lead to the next 
imaging agent or even a drug for Alzheimer's disease.  Since the nitrogen atom of these 
heterocycles represents a convenient linkage point through N-alkylation, one might 
envisage appending the fluorine tag via a simple fluoroethyl linker (e.g., 26)102,103 or via a 
polyethylene glycol spacer as in 27.104,105 Since modulating the lipophilicity of PET 
imaging is often a critical factor in terms of cell entry and/or wash out from the brain, the 
fluoroethyl group might possibly make the targeting molecule too lipophilic.102 Rapid 
wash out from non-specific binding sites is necessary to obtain good resolution in the 
PET image.106  Introducing the polyethylene glycol moiety between the molecule and the 
fluorine tag decreases lipophilicity, however the size of such a linker might preclude 
binding to certain targets.102,104,105  A third option that is becoming rather popular is using 
fluorethyl azide to introduce the tag to a molecule charged with a propargylic moiety by 







Positron Emission Tomography 
 Positron emission tomography (PET) is an imaging technique that utilizes 
compounds labeled with a positron emitting radioisotope in order to image and measure 
biochemical processes in vivo.112-114 Rapid development of PET has occurred since the 
1970’s with advances in detector systems, improved computing capabilities, and 
advances in radiochemistry.115 Imaging agents that have been developed to date are often 
labeled with 11C or 18F.  Half-life of the radioisotope is an important characteristic to 
consider.  At a mere 20.4 min the half-life of a11C labeled compound requires that a 
facility wishing to employ it to have an on-site cyclotron for production.  The half-life of 
18F, at 109.7min, is more than 5x longer allowing imaging agents bearing this reporter to 
be shipped to distant facilities after production.  This quality alone makes 18F label more 
desirable in most cases.113 
 The development of safe and selective fluorinating agents has allowed for fluorine 






pharmaceuticals has increased.116 Even with the increase in incorporating fluorine into 
more molecules, introducing radioactive fluorine into a molecule for use with PET 
imaging still comes with challenges.116,117 
 Radioactive fluorine is produced in two forms: the electrophilic form and the 
nucleophilic form.  The nuclear reaction 20Ne(d, α) 18F produces [18F]F2 after the addition 
of fluorine-19 carrier gas to remove the very reactive electrophilic form from the target.  
The addition of the carrier gas decreases specific activity and maximum radiochemical 
yield because for each reaction there is only a 50% chance that the radioactive 
electrophilic flourine will react.  This reaction is used only when specific activity is not a 
concern.  The 18O(p, n)18F reaction is used much more often because it employs an 
enriched water target with can be regenerated when the nucleophilic form, [18F]F- , is 
trapped on an exchange resin (commonly K222).  This reaction provides the nucleophilic 
form of fluorine-18, which has high specific activity, in high yields.113,114,117 
 Standard strategy for identifying new potential pharmaceutics involves screening 
a library of compounds for binding to target (biomarker) and finding optimal candidates. 
Then, if a fluorine group was not already present in the precursor molecule, part of the 
molecule would be removed so as to append a fluorine containing prosthetic group. This 
standard strategy is inconvenient because the molecule would have to have biological and 
physical properties re-evaluated.118 This is where the novel idea of Proxy-PET building 
blocks will be very helpful.   
 The idea of Proxy-PET is focused on creating entire libraries of compounds that 






only a few building blocks with cold fluorine incorporated. The building blocks could be 
attached to various compounds to create a new library of potential PET imaging agents 
before screening the library of compounds for binding to target biomarker. If a molecule 
has the desired properties, the 18F can replace the “cold” fluorine and no additional 








Results and Discussion 
 The goal of this project was, first and foremost, to develop “cold” versions of 
potential diagnostic PET imaging agents for use in Alzheimer’s disease in which the 
requisite fluoro “tag” (vide infra) would be appended to the targeting agent via a triazole 
prosthetic group. In the event that the triazole linker impeded binding to the anticipated 
target (tau), these molecules would be studied for alternate purposes such as imaging 
caspases or other targets relevant to AD. 
 In order to image a biological target with a PET scan, a targeting agent with a 
radioactive reporter tag such as 18F or 11C must first be administered to the patient 
(usually intravenously), the imaging agent should then bind to some target of diagnostic 
relevance and the photons emitted upon positron annihilation be detected.  The 18F 
isotope has become the radiolabel most commonly used with PET imaging because of its 
biologic and physical properties as discussed previously.  One might imagine two 
scenarios by which a radioactive 18F-tag might be incorporated into an imaging agent. In 
the first situation, an 18F-atom might be substituted in place of a fluorine atom already 
present in a targeting agent with a demonstrated affinity for the target of interest.  
Alternatively, an 18F-atom might be appended to the targeting agent by means of some 
prosthetic or linking group which ideally would not impede affinity for the target. 
However, since less than 30% of molecules of therapeutic interest contain fluorine in 






stratagem, although this sometimes changes the physical and biological properties of the 
composite molecule possibly rendering it inactive.117 
 As many groups recently have also done as a means of appending the fluorine tag, 
we chose to explore the use click of chemistry, specifically, the Cu(I)-catalyzed azide-
alkyne 1,3-dipolar Huisgen cycloaddition (CuAAC).118This copper mediated reaction 
was first demonstrated by Sharpless and Meldal119,120 to regioselectively produce 1,4-
disubstituted-1,2,3-triazolesand has become increasingly popular as a means of rapidly 
introducing radiolabeled tags for use with PET. Azides and alkynes are essentially inert 
to most biological conditions and will only react with each other;119,121 a feature termed 
orthogonality. Additionally they are small in size and can easily be introduced into 
organic compounds.121,109 
 In developing an imaging radiotracer by the “click labeling” process, a library of 
compounds is normally synthesized around a certain targeting scaffold and screened for 
optimal binding to a relevant diagnostic cellular target. Upon identification of an optimal 
binding substrate, an alkynyl substituent is introduced at some position deemed non-
critical for binding, whereupon the triazole linked 18F-reporter can be introduced by a 
click process with [18F]fluoroethyl azide ([18F]FEA) (vide infra) and the radiolabeled 
composite molecule then reassessed for affinity to the target.118 
 In order to avoid the possibility that introduction of a radiolabeled prosthetic 
group interferes with binding to the ultimate biological target in the normal discovery 
paradigm, the so-called Proxy-PET concept was developed at WSU and detailed herein. 






the commonly employed fluoroethyl triazole appendage must be present in any eventual 
imaging agent based upon this prosthetic group, building blocks incorporating “cold” 
versions of this requisite feature might be prepared and utilized early on in the discovery 
process. With such a cold reporter group present in the initial binding assays it can be 
readily appreciated that an optimal targeting agent, once discovered, represents the de 
facto PET imaging agent when prepared with an 18F-reporter.  
 It is important to consider why the 1,2,3-triazole group would make a good 
prosthetic group to append the fluorine tag into a molecule.  The 1,2,3-triazole moiety 
possesses a moderate dipole character as well as hydrogen bond acceptor capabilities due 
to the ring nitrogen atoms, and is stable under in vivo conditions. Additionally, triazoles 
are resistant to cleavage hydrolytically or otherwise and are almost impossible to oxidize 
or reduce.122Employing the triazole ring as a linker is expected to be advantageous with 
regard to the pharmacological properties of a molecule because of biologically favorable 
modifications110 such as altered lipophilicity and polarity123 as well as providing a 
surrogate for the amide bond.124 
 Marik and Sutcliffe were the first to employ the CuAAC reaction to label a 
protein with 18F-fluorine by coupling 3-azido-propionic acid (29) to the N-terminus of a 
protein30 and then ‘clicking’ it with a terminal fluoroalkyne 32 to form the triazole as 
seen on the protein labeled 33. This illustrated that the CuAAC reaction was a very fast 
and efficient method to radiolabel peptides/proteins with 18F for targeted imaging using 
PET.107 Furthermore, Hausner used the method developed by Marik and Sutcliffe to label 
a protein and illustrated how the introduction of the triazole ring does, in fact, have a 






mentioned characteristics.125 The triazole linked 18F-reporter 33 was compared to two 
analogues capped with typical acyl linkers (e.g. 34 and 35)which were introduced to the 
protein 30 at the N-terminus via condensation reactions. The fluorinated tag 36 was 
introduced via a click reaction as described previously.  The 3-labeled proteins were 
injected into mice and in vivo characteristics such as concentration in certain organs and 
metabolism were studied.  This was the first time that a radiotracer that had been 
introduced via CuACC was studied in vivo and it was concluded that the “clicked” 
radiotracer can be considered comparable to other radiotracers; however there were 
noticeable differences in pharmacokinetics between each radiotracer underlining the 
importance of investigation of each linking group.125 
 
 
 An alternative method to introducing 18F via the CuAAC reaction would be to 
attach the 18F to the azide moiety as in the case of [18F]fluoroethylazide ([18F]FEA) (37), 
and then clicking with an alkyne that had been pre-installed in a protein (e.g. 38). In 
2007, Glaser and Aarsted first synthesized [18F]FEA by nucleophilic fluorination of 2-
azidoethyl-4-toluenesulfonate (40) with anhydrous no-carrier-added Kryptofix 2.2.2 






K+[18F]F-.This was done in acetonitrile (ACN) and after 15min the [18F]FEA was isolated 
via flow-and-trap process.103 Other groups have developed alternative syntheses of 
[18F]FEA over the years, but all involved some sort of distillation procedure to purify the 
product such as flow-and-trap or vacuum trap-to-trap.  In 2015, Zhou et al. developed a 
method to synthesize and isolate [18F]FEA without distillation. A series of solid phase 
extraction cartridges were used to purify the radioisotopically labeled FEA (that had been 
synthesized in the same method as previously described) to increase radiochemical yields 




 The examples cited so far involved reporter groups that were introduced onto a 
peptide but there is interest in labeling small drug like molecules.  In 2009, Nguyen et al. 
developed the first small molecule that was labeled with 18F via the CuAAC reaction. The 
molecule that Nguyen developed was prepared from an isatin 5-sulfonamide derivative 
41 that had been N-alkylated with propargyl bromide and then clicked with [18F]FEA 
(37) in the presence of CuSO4 and sodium ascorbate to yield 42.  This molecule was 






discovery was especially important for many reasons.  One, it showed that a small 
molecule could be labeled with the triazole linker.108 Moreover, the small molecule 
entailed a scaffold which was one of the backbones to which we envisioned attaching our 
building blocks.  
 
 As stated at the outset, we envisioned synthesizing cold “building blocks” using 
click chemistry.  The term building block was used because these molecules would 
incorporate a non-radioactive FEA moiety into a molecule (via the CuAAC reaction) that 
would also contain a linking functionality that would be used to append the “block” onto 
other molecules.  The development of these building blocks as well as how and why they 
were introduced to other molecules will be detailed within this section.  
 Before a fluorine containing building block could be produced, it was necessary 
to develop an efficient synthesis of 2-fluoroethyl tosylate (45).  Once in hand, it was 
anticipated that it could later be reacted with NaN3 and a propargyl moiety in a one pot 
synthesis to produce the desired triazole containing building blocks. 
 To this end, 2-fluoroethanol (43) was treated with p-toluenesulfonyl chloride (44) 









 This method was modified from a preparation described by Shealy in a U.S. 
patent.128The original method called for tosyl chloride (44) to be added to EtOAc chilled 
in an ice bath and then 2-fluoroethanol (43) and triethylamine (premixed) were to be 
added dropwise over 30min, the reaction stirred in an ice bath for 3h and then put in the 
refrigerator overnight.  The next day the triethylamine hydrochloride that had formed 
would be filtered off and the filtrate diluted with hexane to induce precipitation of the 
product.  The modified method consisted of adding all the reagents except for the 2-
fluoroethanol (43), which was then added dropwise over 15 min, after which time the 
reaction was stirred at rt for an additional 20 h.  The product was then purified via 
column chromatography using hexanes:ether (1:1).  Due to reoccurring low yields, three 
initial samples of this product were combined for characterization and the 1H and 13C 
NMR as well as GCMS spectra of this composite mixture were obtained.  
 In the 1H NMR spectrum of 45 (Figure 2), the multiplet at 7.84-7.80 ppm, labeled 
c represents the two H’s on the aromatic ring closest to the SO2, whereas the multiplet d 
at 7.39-7.36 ppm corresponds to the two H’s on the aromatic ring nearest the methyl 
group.  Both of these peaks are expected to be doublets and one can see they resemble 
doublets with a few extra tiny peaks at the base of each peak.  The four multiplets labeled 
a and b between 4.68 and 4.31 ppm correspond to the four H’s on the ethyl moiety. There 
are four multiplets instead of two because of the splitting caused by the fluorine atom. 






The two multiplets labeled a represent the two hydrogens on the carbon adjacent to the 
fluorine, while the multiplets labeled b are the hydrogens on the carbon adjacent to the 
oxygen. These peaks are expected to be doublets of triplets due to splitting by the fluorine 
(doublet) and by neighboring methylene hydrogens (triplet). It can be seen in the 
spectrum that the pattern is consistent with doublets of triplets (with a few additional 
peaks represented within each triplet). Finally, the singlet, e, at 2.47 ppm integrates to 3H 
and represents the H’s of the methyl group.129 
 
Figure 2- 1H NMR Spectrum of 2-fluoroethyl tosylate (45) 
 The 13C NMR of 45, Figure 3, shows nine peaks when there are only seven 
unique carbons.  This is because of splitting caused by the ½ spin interaction of the two 
carbons closest to the fluorine. The set of peaks labeled a and b are actually doublets and 
represent the two CH2 carbons (JC-F=173.5 Hz and JC-F=21.23 Hz respectively).  The 
peak at 145.1 ppm labeled c represents the quaternary carbon with the same label; it is 






represents the quaternary carbon adjacent to the methyl group.  The peak at 129.9 ppm 
labeled d represents two carbons on the aromatic ring closer to the sulfonyl group and the 
peak at 127.9 ppm labeled e represents the other two carbons on the ring ortho to the 
methyl moiety.  Finally, the peak at 21.6 ppm, g, represents the methyl carbon. The peaks 
represented match literature values closely.129 
 
Figure 3- 13C NMR spectrum of 2-fluoroethyl tosylate (45) 
 As mentioned earlier, our group could initially only obtain this product in low 
yield and thus it was deemed necessary to purchase 2-fluoroethyltosylate (45) 
(ChonTech).  Although this molecule was relatively expensive to purchase, the 2-
fluoroethanol (43) starting material was also costly and one would need a 50% yield 
every time to make buying the starting material more cost effective than buying the 
product.  Most of the molecules made using 2-fluoroethyl tosylate (45) in this thesis were 
made using the purchased variety versus the synthesized variety. However, since we 
initially tried to make 2-fluoroethyl tosylate in 2013, an intern in our lab (John van Vliet) 






 To gain experience with performing click reactions, before using the expensive 2-
fluoroethyltosylate, a known compound 49 was synthesized to test reaction parameters. 
The compound was produced by reacting benzyl bromide (46) with sodium azide (47) 
and propargyl alcohol (48) in the presence of copper sulfate and sodium ascorbate in, at 
first, tBuOH/H2O as a solvent based on reactions reported by Fokin and Sharpless.119 
While these authors used copper sulfate and sodium ascorbate in catalytic amounts of 1 
mol % and 5 mol %, respectively, we chose to increase the proportions of these species to 
5 mol % and 10 mol % as described by Rivero.131 Although this reaction was successful, 
yields at first were not particularly desirable, ranging from 3% to 33.3%.  In looking for 
ways to improve upon this process, we noted that several groups had success synthesizing 
1,2,3-triazoles in the most environmentally friendly solvent, H2O.132-134 Of the groups that 
used H2O, Kacprzak134 utilized the CuSO4*H2O and sodium ascorbate catalyst system as 
described previously, however the other groups employing water used different catalysts 
such as Cu/C and Cu(II) acetate.132,133 Unfortunately, in the present work, when the 
reaction was attempted using water as the only solvent, the reaction was unsuccessful.  A 
group in 2007 had performed this same reaction in EtOH/H2O (1:1) in the presence of 
triethylamine (TEA)135 and obtained almost 100% yield.  Attempting this reaction under 
those conditions led to production of 49 in greater than 90% yield.   
 46 






 The structure of 49 was confirmed via 1H and 13C NMR; further evidence was 
corroboration with literature melting point and published NMR data.131Comparison of 
experimental data to data of a fully characterized product confirmed 1-benzyl-4-
(hydroxymethyl)-1H-1,2,3-triazole (49) had been produced. 
 In the 1H NMR spectrum of 49 (CDCl3) the peak labeled e, at 7.47 ppm, is a 
singlet representing the proton on the triazole ring.  The multiplet at 7.40-7.31 ppm 
represents three (a, b, b,) of the protons on the benzene ring while the multiplet at 7.28-
7.21 ppm represents the remaining two protons (c, c) on the benzene ring.  The benzylic 
methylene CH2 (d) located between the benzene ring and the triazole ring is represented 
by the singlet at 5.48 ppm, while the other singlet at 4.7 ppm represents the other CH2, 
labeled f, adjacent to the alcohol functional group.  The protons at d were located further 
down field because of their proximity to the triazole nitrogens. Finally, the hydroxyl 
proton labeled g is represented by the broad peak at 4.0 ppm. 
 







 Following is another 1H NMR spectrum of compound 49.  This spectrum was 
collected on compound 2 in DMSO-d6 rather than CDCl3.  There are some noticeable 
changes when solvents are changed.  Most notably the downfield shift of the hydrogen, 
labeled g, of the OH group shows the effect of the DMSO-d6 on this molecule. This shift 
is due to the OH group interacting with DMSO-d6 which is a strong hydrogen bond 
acceptor.   
 
Figure 5- 1H NMR (DMSO-d6) spectrum of 1-benzyl-4-(hydroxymethyl)-1H-1,2,3-
triazole(49) 
 The 13C NMR of compound 49, Figure 6in CDCl3, shows the eight peaks 
expected. This is because one of the quaternary carbon peaks is not showing up. The 
quaternary carbon, labeled g is predicted to appear at 148.2 ppm,131 and can be observed 
in this spectrum at 148.9 ppm. The peak at 136.6 ppm represents the quaternary carbon 
labeled d. Peaks at 129.2, 128.5, and 128.4 ppm represent c, a, and b, five of the carbons 






ring.  The placement of the C-H labeled f was determined via a DEPT90 13C NMR. The 
carbon of the CH2 between the rings is labeled e and appears at 54.2 ppm, whereas the 
carbon of the CH2 adjacent to the OH moiety, labeled h, is represented by the peak at 
56.1 ppm. 
 
Figure 6- 13C NMR (CDCl3) spectrum of 1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole 
(49) 
 As mentioned before, this reaction using the inexpensive surrogate benzylic 
bromide (46) was first attempted using tBuOH/H2O as solvent and as before initial 
attempts at the click reaction of propargyl alcohol (50) with 2-fluoroethyl tosylate (45) 
and sodium azide in the presence of copper sulfate/sodium ascorbate in tBuOH/H2O were 
not encouraging.  Upon utilization of the EtOH/H2O and triethylamine system,131[1-(2-
fluoroethyl)-1H-1,2,3-triazol-4-yl]methanol (51) was obtained in good yields [via the 
intermediacy of fluoroethyl azide (37)].This keystone building block, while potentially 
amenable to Mitsunobu type couplings to substrates, could also be converted to a variety 











 The 1H NMR of compound 51 (CDCl3) shows six sets of peaks due to the 
splitting caused by the ½ nuclear spin of fluorine.136,137 1H has a ½ nuclear spin also 
which is why the fluorine can cause splitting in the 1H NMR.  The singlet peak labeled c, 
at 7.68 ppm, is assigned to the proton on the triazole ring.  The multiplet labeled a, at 
4.87 ppm corresponds to one of the multiplets arising from the CH2 adjacent to the 
fluorine.  The other multiplet of this group overlaps one of the multiplets from the 
adjacent CH2 group labeled b and centered at 4.71 ppm. The other multiplet b arises from 
the CH2 of the ethyl moiety farthest from the fluorine and occurs at 4.62 ppm.  The 
splitting of both sets of methylene hydrogens is attributed to coupling to the adjacent CH2 
group as well as the fluorine atom ipso or one carbon away.  These peaks resemble a 
doublet of triplets, however the splitting is not first order so J values cannot be 
determined.  The singlet at 4.79ppm, labeled d, represents the two hydrogens next to the 
hydroxyl group. Finally, the proton of the hydroxyl group is represented by the broad 











Figure 7- 1H NMR (CDCl3) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methanol(51) 
 Again, upon switching solvent to DMSO-d6, changes are observed in the 
spectrum. Unlike the case of compound 49, where only minor changes upon switching 
solvents were observed, there are significant changes in the spectrum of compound 51 in 
DMSO-d6.  Most notable again is the change in the hydrogen labeled e (the hydroxyl 
hydrogen); once a singlet at 2.98 ppm in CDCl3, it now appears as a triplet at 5.22 ppm 
(JH-H=5.65 Hz). The chemical shift of the protons labeled d adjacent to the OH group was 
also affected: as the singlet at 4.79ppm is now a doublet at 4.52 ppm.  The splitting (JH-







Figure 8- 1H NMR (DMSO-d6) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methanol (51) 
 The 13C NMR (CDCl3) of compound 51 shows seven peaks when only five 
carbons are present in the molecule.  This is due to the two CH2’s between the triazole 
ring and the fluorine being split each other as well as by the fluorine.  The most 
downfield peak at 148.1 ppm, labeled d, represents the quaternary carbon in the triazole 
ring. The peak labeled c, at 122.8 ppm, is assigned to the other carbon in the triazole ring.  
These carbons were assigned based on where they appeared in compound 49. The doublet 
at 81.5 ppm, labeled a, is the carbon adjacent to the fluorine (JC-F=177.9 Hz).  Greater 
splitting is observed with carbon a than at the carbon labeled b, at 50.5 ppm (JC-F =20.5 
Hz) because of the proximity to the fluorine.  The C adjacent to the OH group is labeled e 
and represented in the spectrum at 56.2 ppm. 
 
Figure 9- 13C NMR (CDCl3) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methanol (51) 
 Having this primary building block in hand, it was envisaged that 51 might be 






tosylate) by a series of simple reactions. First though, we again turned to the benzyl 
surrogate 49 to test out methods, making sure they would work with a similar more 
robust molecule before attempting the reactions on 51. 
 Oxidation of 49 with MnO2 led to smooth conversion to the corresponding 
aldehyde52while reaction with PBr3 afforded the alkyl bromo derivative 53. Since it was 
believed that the carboxylic acid 56 could be prepared from the analogous click reaction 
involving propiolic acid (54), an oxidative route to 56 was not explored. 
 
Scheme 1 
 Treatment of compound 49 with MnO2 in dichloroethane (DCE) for 18h at 80ᵒC 
yielded the aldehyde 52 in 73% yield. Anticipated uses of such triazole aldehydes include 
appending to substrates via aldol type reactions or via reductive amination processes. The 
1H NMR of compound 52 (DMSO-d6) confirms that the alcohol derivative 49 was in fact 














one CH2 signal represented.  The benzene carbons are represented by the multiplet 
labeled a (7.39-7.35 ppm), and the CH2 between the benzene ring and the triazole ring is 
still near where it was before moving from 5.59 ppm in compound 49 to 5.71 ppm (peak 
b) in compound 52.  The peak at 10.03 ppm, labeled d, represents the proton that is part 
of the aldehyde functional group.  Finally, proton c representing the proton on the triazole 
ring appears at 9.00 ppm. 
 
Figure 10- 1H NMR spectrum of 1-benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52) 
 The 13C NMR spectrum also confirms the production of the compound 52.  
Carbon h is furthest downfield appearing at 185.4 ppm which is typical of an aldehyde 
carbonyl group. The quaternary carbon in the triazole ring is represented at 147.5 ppm 
and labeled g. The peak labeled f corresponds to the CH in the triazole ring and is at 
135.8 ppm.  The carbon labeled g is shifted further downfield because of its proximity to 
the aldehyde.  The four non-equivalent benzene carbons are represented as follows:129.3 
ppm, peak c, 128.8 ppm, peak d, 128.7 ppm, peak a, and 128.6 ppm, peak b.  Finally, the 







Figure 11- 13C NMR spectrum of 1-benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52) 
 The bromo derivative 53 was produced by adding 49 to PBr3 in DCM.  The 1H 
NMR and 13C NMR spectra confirm the production of compound 53.  The 1H NMR 
spectrum shows the absence of the broad hydroxyl peak, which is the only major 
difference from the 1H NMR spectrum (CDCl3) of the starting material.  
 
Figure 12- 1H NMR spectrum of 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53) 
 In the 13C NMR spectrum of compound 53 all the peaks remained unchanged 








carbon was next to a hydroxyl group whereas now it is adjacent to bromine. Carbon h is 
now represented at 21.5 ppm when before it appeared at 56.1 ppm.  However, in this 
spectrum peak g (145.0 ppm) representing the quaternary carbon in the triazole ring is 
present more clearly.  
 
Figure 13- 13C NMR spectrum of 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53) 
 It is interesting to note that while this bromomethyl compound was originally 
made as a surrogate to examine the critical reaction process and the functional group 
interconversion of an alcohol to a bromo derivative, this group could also be used to 
practice the N-alkylation of an isatin to yield a triazole linked potential imaging agent. It 
turns out that this triazole moiety had already been put at the N-position of isatin but not 
by the same method as employed herein.  The other group first N-alkylated with 
propargyl bromide and then clicked on the benzyl azide 55 moiety.138 Discussion of how 
and why 53 was introduced onto isatin will follow. 
 The method used to produce compound 49 was again used to produce the acid 
derivative 56.  The only difference was that propiolic acid 54 was added in place of 
propargyl alcohol.  The workup was a little different too, in that with compound 56, since 






 The 1H NMR of compound 56 confirms that a compound containing a triazole 
ring was produced however not necessarily the carboxylic acid.  The multiplet labeled a, 
b, c represents the protons on the benzene ring.  The hydrogen, labeled f, associated with 
the carboxylic acid moiety is not represented in this 1H NMR.  If it were to be visible it 
would appear at about 11.4 ppm as a broad peak.  A broad peak in this region was 
detectable but only upon peak enhancement.  Based on this data it cannot be confirmed 
that the carboxylic acid was produced.   
 
Figure 14- 1H NMR spectrum of1-benzyl-1H-1,2,3-triazole-4-carboxylic acid (56) 
 The 13C NMR of compound 56 also differs from compound 49 but it does not 
definitively confirm the presence of the carboxylic acid functionality. The patterns in 
which the peaks appear in this spectrum are different than those of the alcohol derivative 
49 however they do not confirm the product was produced. The melting point of the 
product 56 was much higher than the alcohol 49 which indicated that the acid had been 








Figure 15- 13C NMR spectrum of 1-benzyl-1H-1,2,3-triazole-4-carboxylic acid (56) 
 The carboxylic acid would be potentially useful to cap a peptide as shown in the 
example reaction on page 24.  However, we did not use the compound in any subsequent 
reactions because peptides were not used in this thesis. 
 After it was determined that the MnO2 and PBr3 reaction worked well with the 
benzyl surrogate, to develop additional building blocks the reactions were attempted with 
the desired fluoroethyl derivative 51. Although oxidation with MnO2 led to smooth 
conversion to the corresponding aldehyde 58, reaction with PBr3 failed to efficiently 
afford the bromo derivative 59.  The carboxylic acid derivative 60 was prepared via 
addition of propargylic acid (54) to fluoroethyl azide (37) under the same conditions as 
used in the attempted preparation of 51. Compound 60 had NMR data to suggest it had 
been created, however the sample was too impure to report and since this was not the 
building block we were going to use in the near future the reaction was abandoned and 







 The 1H NMR of the aldehyde derivative 58 provides confirmation of structure.  
The peak located at 10.11 ppm, labeled d, represents the H of the aldehyde moiety. A 
singlet labeled c, at 8.27 ppm, represents the one proton on the triazole ring.  The two 
multiplets centered at 4.91 ppm and 4.81 ppm represent the two protons adjacent to the 
fluorine labeled a; whereas the multiplet at 4.75 ppm represents the two protons labeled 
b.  The splitting here is, in the case of the protons labeled a, caused by the neighboring 
fluorine and CH2.  These peaks confirm the production of the aldehyde because of the 
similarities to the spectrum of the starting material 51 (Figure 7) as well as the peak at 
10.11 ppm which is indicative of an aldehyde function group and is not present in the 
starting material spectrum. 
51 











Figure 16- 1H NMR spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde (58) 
 Additionally, the 13C NMR spectrum (Figure 17) confirms the starting material 51 
was converted to the aldehyde 58.  The peak furthest downfield at 184.8 ppm, labeled e, 
is representative of an aldehyde carbonyl group.  The peak at 147.9 ppm, labeled d, 
corresponds to the quaternary carbon also labeled d. Peak c at 126.5 ppm is due to the C-
H in the triazole ring; this peak is shifted downfield compared to the starting material 51, 
where it appears at 122.8 ppm.  The peaks labeled a at 81.5 ppm (midpoint), 
corresponding to the C adjacent to the fluorine, appears at the same position as in the 
starting material.  Finally, the peaks labeled b at 50.9 ppm (midpoint) represent the 







Figure 17- 13C NMR spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde (58) 
 An elemental analysis was completed on this molecule 58 and the results 
confirmed the C, H, and N percentages were within 0.4% of the calculated value for the 
expected structure.  Since the alcohol starting material 51 exists as an oil and it was not 
possible to obtain an elemental analysis for it; the conclusion that 51 had been produced 
based on the results of the elemental analysis on the aldehyde derivative 58. 
 After many unsuccessful attempts to produce and isolate the bromo derivative 59, 
it was envisaged that tosylation of the alcohol derivative 51 could be an alternative route 
to producing a building block that would be introduced via N-alkylation.  Again it was 
elected to test reactions on 49 before attempting them with 51. Upon researching the 
topic it was found that the tosylation of benzyl alcohols has been accomplished many 
times over the years; employing various methods that seemed relatively simple.139-143 
However, after attempting to tosylate benzyl alcohol (as a model study) four times with 
no formation of product, it became apparent that tosylation of such species was difficult. 






investigation of the aza-Prins reaction”. In this paper, Dobbs et al. added the alcohol 62 to 
be tosylated to DCM, cooled the solution to 0ᵒC and then added 4-
dimethylaminopyridine (DMAP), tosylchloride (44) and triethylamine in portions.  The 
reaction was held at 0ᵒC until complete as determined via thin layer chromatography 
(TLC).142 In the present work, the first attempt consisted of adding all the reactants to a 
vial at once and letting it stir at room temp for 4h.  The reaction was chilled because of a 
procedure from a patent that stated the reactions were successful at 25ᵒC.143After two 
failed attempts, the reaction conditions were modified slightly.  Thus, the reaction 
mixture was chilled, the TEA was added dropwise over 5 min and then the benzyl alcohol 
was added dropwise.  Once all the reactants were added the temperature was allowed to 
reach rt and stirred for an additional 48 h.  Based on TLC examination, the product was 
never formed as the Rf of the “product” matched the Rf of the starting material even after 
reacting for 48 h.  For the final attempt the reaction was kept colder for an extended 
period of time which resulted in failure also. Finally, an article was discovered that 
supported these negative findings, it was titled “Treatment of Alcohols with Tosyl 







 In order to utilize the aldehyde 58, isatin (23) and 5-chloro isatin (64) were 
reduced to the corresponding oxindoles 24 and 65, respectively.  This was accomplished 
using 80% hydrazine hydrate over 4 h while refluxing.  
 
 As outlined in the introduction, oxindole and isatin scaffolds were chosen because 
of their “privileged”nature.96 Oxindoles have a broad range of biological activities, 
including protein kinase inhibitors,98 and possible caspase inhibitor,145 cdk5 inhibitor,146 
and casein kinase inhibitor.  Isatins have been shown to inhibit caspase-3/7.108 
 To demonstrate the usefulness of the building blocks produced as a means of 
appending a fluoroethyl group to a scaffold of interest, the aldol reaction of 5-chloro-2-
indolinone (65) and aldehyde 58 was explored; the reaction was effective to yield 67. 
Likewise,the aldol reaction between 2-indolinone (24) and aldehyde 53 was also effective 
to yield 66. It can readily be seen that N-alkylation of this substrate would yield a new 







 The 1H NMR and 13C NMR spectra of 66 and 67 confirm the structures of the 
products synthesized.  Elemental analyses were completed for both molecules 66 and 67 
and the results confirmed the C, H, and N percentages were within 0.4% of the calculated 
values for each of the molecules. 
 Compound 67 exists as a mixture of E and Z isomers which was determined by 
the 1H NMR spectrum.  Traditionally, E and Z isomers of benzylidene oxindoles are 
determined based on the chemical shifts of the aromatic protons on the benzylidene ring 
(H-2ꞌ and H-6ꞌ) as well as the shift of the vinylic proton.147 Compound 67 is similar to but 
not actually a benzylidene oxindole, but due to the lack of a model compound of this 
type, we have likened the proton of the triazole ring to the H-2ꞌ proton present in a 
benzylidene oxindole.  Additionally, the vinylic proton can be used as a reference as to 
ascertain which isomer is present as well.  The E-isomer has a vinylic proton that is more 
deshielded due to the influence of the C-2 carbonyl causing a downfield shift. The H-2 
and H-6 protons (ortho-benzylidene protons) are affected by the C-2 carbonyl also.  
Deshielded protons will be shifted further downfield compared to their shielded 
counterparts.  In the case of compound 67 there is only one quasi “ortho” proton to 






between 7.45-7.84 ppm, whereas ortho protons in the Z isomer will appear between 7.85-
8.53 ppm.  The vinylic proton exhibits chemical shifts as a consequence of shielding also, 
however in the E isomer the vinyic proton is deshielded appearing around 7.84 ppm and 
in the Z isomer is shielded appearing at about 7.55 ppm.147,148 
 In the 1H NMR of 67 the peak furthest downfield at 10.8 ppm, labeled h, 
represents the proton on the nitrogen.  It is shown as two singlets because of the presence 
of both the E/Z isomers.  The peaks labeled c, also two singlets, at 9.45 ppm and 8.78 
ppm, are assigned to the “ortho” proton on the triazole ring. The peak at 9.45 ppm 
indicates there is 30% Z isomer and the peak at 8.78 ppm designates 70% E isomer.  The 
two doublets labeled d, represent the vinylic proton.  The doublet at 9.16 ppm represents 
the E isomer 70% and the other doublet 7.99 ppm is assigned to the of the Z isomer 30%.  
The singlets at 8.06 ppm and 7.62 ppm, labeled e, are representing the Z and E isomers of 
the proton next to the chlorine respectively. Proton f is represented as a doublet of 
doublets of doublets at 7.29 ppm and proton g at as an odd looking triplet at 6.88 ppm.  
The multiplet at b represents the protons adjacent to the triazole ring whereas the singlet 







Figure 18- 1H NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-5-chloro-1H- indol-2-one (67) 
 The 1H NMR of compound 66 indicates that only one isomer is present, unlike 
compound 67 which was 70:30 E/Z.  The singlet at 10.73 ppm represents the proton on 
the nitrogen.  The singlet at 9.44 ppm, labeled c, is indicative of the hydrogen of the 
triazole ring.  The final singlet, d, appearing at 7.90 ppm, is associated with the vinylic 
proton. Based on comparison with the vinylic and C-2 proton in the 1H NMR of 
compound 67 it can be determined that this compound (66) exists as the Z isomer 
(100%).  Proton e, is represented by the doublet (JH-H=7.51 Hz) at 7.80 ppm; the splitting 
is caused by the adjacent proton f.  Proton f, a triplet at 7.23 ppm (J=7.61 Hz) and is split 
by two neighboring hydrogens (e and g) both ortho. Proton g is also a triplet split by two 
neighboring hydrogens; the peak appears at 6.99 (J=7.52 Hz).  The doublet at 6.87 ppm 
represents proton h, which is split by the ortho hydrogen g (J=7.72Hz).  The multiplets, a 
and b, at 4.94 ppm and 4.81 ppm represent the CH2 adjacent to the triazole ring and the 







Figure 19- 1H NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-1H-indol-2-one (66) 
 The13C NMR of 67 is shown next, where in peaks were estimated using 
nmrdb.org predicting program.  The peak labeled h is furthest downfield as it should be 
since the carbon it represents is attached to the ketone moiety.  The peak labeled l and the 
peak labeled m correlate to the ethyl moiety and the peaks appear as they did in the 








Figure 20- 13C NMR spectrum of  3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-5-chloro-1H- indol-2-one (67) 
 The 13C NMR of compound 66 resembles the 13C NMR of compound 67 with the 
carbon attached to the double bond oxygen furthest downfield and the ethyl carbons 
furthest upfield.  The ethyl moiety is represented more clearly in this spectrum.  
 
Figure 21- 13C NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-1H-indol-2-one (66) 
 As suggested previously, N-alkylation of compounds 66 and 67 would yield a 
new library of compounds of PET ready targeting agents. The N-2,6-difluorobenzyl 
fragment had previously been shown by the Ketcha group to enhance the cell-death 
inhibitory properties of benzylidene oxindoles (presumably by inhibiting caspase-3). This 
caspase inhibitory fragment was therefore appended onto the C-3 triazolyl oxindole by N-







 The 1H NMR of compound 69 confirms its stucture.  Comparision to the 1H NMR 
of the starting material 66 shows that the peak at 10.73 ppm assigned to the proton at the 
N-1 position is not present in the product.  The singlet furthest downfield at 9.58 ppm, 
labeled c, corresponds to the proton on the triazole ring, which appears at 9.44 ppm in the 
spectrum of the starting material 66. The second singlet at 7.85 ppm, labeled d, appeared 
at 7.90 ppm in the starting material and represents the vinylic proton. The protons of h, f, 
g, and e; indicating the aromatic protons of the oxindole backbone, all of which were 
represented in the spectrum of 66 also.  The additional protons labeled k and j at 6.91 
ppm as a multiplet represent the three protons on the aromatic ring that was added. 
Additionally, the peak labeled i represents the CH2 between the nitrogen and the 
difluorobenzyl group.  Finally, the ethyl moiety attached to the triazole ring is 







Figure 22- 1H NMR spectrum of3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-1-[(2,6-difluorophenyl)methyl]-1H-indol-2-one (69) 
 The 13C NMR of compound 69 can be compared to the 13C NMR of compound 66 
to determine if the N-alkylation has occurred.  The peak at 36.8 ppm labeled n confirms 
the presence of the benzylic carbon.  Additionally it is important to note the appearance 
of 4 additional peaks in the aromatic region due to the 4 unique carbons on the 
difluorobenzyl moiety.  Software was used to help assign carbons in the aromatic region 
due to the sheer number of carbons (nmrdb.org). 
 







 Although a library of N-triazole linked benzylidene oxindoles reporter groups 
were initially envisaged as arising via the N-alkylation of a sublibrary of N-H 
benzylidene oxindoles, it was also deemed valuable to initially N-alkylate an isatin with 
an appropriate triazole based alkylating agent and then conduct a reductive 
deoxygenation/aldol sequence. To that end, the bromo derivative 53 was used to directly 
alkylate isatin (23) using KF/alumina (6 equiv) in acetonitrile to afford an N-linked 
triazole isatin 70. The use of KF/alumina as a solid-supported base was first introduced in 
1979 by Ando et al.149 and the Ketcha group has been using it to N-alkylate isatins since 
2011.150,151 The main advantage of employing KF/Alumina as a base for abstraction of 
the isatin N-H involves its being easily removed from the reaction mixture by simple 
filtration. In this case, possibly due to this basic catalyst, the reaction product was 
contaminated with impurities. 
 
 First and foremost, molecule 70 was synthesized to demonstrate how the bromo 
building block could be used to create a “tertiary building block” of sorts (in anticipation 
of reduction and diversification by aldolization).  Secondly, this molecule is an isatin 
derivative, which is significant because in 2008 Aboagye designed a caspase-3/7 
inhibitor, and possible imaging agent, that had the isatin core as a critical part of its 









Jiang and Hansen99 confirmed that the triazole ring at the N-position enhanced caspase-3 
inhibition relative to an N-benzyl substituent, thus demonstrating the value of N-linked 
triazole isatins.  One of their most potent caspase inhibitors contained a benzyl group 
attached to the triazole ring in a disubstituted pattern.100 
 
 
 Ultimately, the goal was to show that being able to produce this N-alkylated isatin 
building block 70, which may not be useful in the development of an imaging agent, may 
be very useful in creating a caspase-3 inhibitor.  
 The 1H NMR and 13C NMR spectra of compound 70 confirm its structure.  
Additionally, in this case there exists a literature melting point and NMR for comparison.  
In the following 1H NMR spectrum (Fig. 24) each proton is represented.  The multiplet 
that is furthest downfield at 7.58-7.56 ppm represents three protons: because of the shift 
of this set of peaks, it can be determined they represented three of the four protons on the 
isatin portion of the molecule, labeled g, i, and j. The next multiplet at 7.31-7.24 ppm is 
integrated as 6H; it is believed that the protons labeled b (x2),c (x2), a, and e are 
represented by this group of peaks because the latter are all aromatic protons and thus are 







doublets at 7.11 ppm.  The splitting is caused by the protons that are ortho to c (JH-H=7.54 
Hz) and the proton that is meta to this proton (JH-H=0.73 Hz).  At 5.49 ppm two protons, 
labeled f, (located between the triazole ring and the nitrogen on the isatin), are 
represented by a singlet. The final peak at 4.99 ppm, labeled d, is also a singlet and is 
associated with the two protons that exist between the triazole ring and the benzene ring. 
Figure 24- 1H NMR spectrum of 1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H- indole-
2,3-dione (70) 
 The 13C NMR of this structure 70 also confirms the N-alkylation of the isatin.   
The peak furthest downfield at 183.0 ppm, labeled f, is indicative of the ketone carbonyl 
carbon, while the peak labeled g, 157.9 ppm represents the carbon of the amide function.  
Peak h, at 150.2 ppm is attributed to the quaternary carbon next to the nitrogen in the 
isatin moiety.  The peak at 142.1 ppm, labeled j represents the quaternary carbon on the 
triazole ring.  Between peak j and peak a, 142.1-111.5 ppm the positions of most of these 
peaks were estimated using the free internet program offered at nmrdb.org.  The peak 
labeled i, at 54.4 ppm, is the C between the triazole ring and the isatin moiety. Finally, 
the peak at 35.4 ppm is the C between the benzene ring and the triazole ring.  These two 






peaks appear in the bromo derivative 53 too, which makes it easier to determine which 
peaks represent the appropriate carbon atoms. 
 
Figure 25- 13C NMR spectrum of1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole-
2,3-dione (70) 
 Having demonstrated the concept of utilizing a surrogate PET building block (i.e., 
triazole alkylating agent) to produce a new type of building block, it was necessary to 
demonstrate the reductive deoxygenation of such N-triazole linked isatins using 
hydrazine. In the event, the reduction of 70 to 72 worked very well which suggests that it 
will be possible to further derivatize such N-alkylated building blocks at the 3-position 







  The1H NMR of compound 72 (Fig 26) confirms its structure.  When compared to 
the 1H NMR of compound 70, the starting material, two extra peaks are observed in the 
proton NMR due to the reduction of the ketone at the C-3 position. The protons labeled k 
are represented as two doublets at 10.53 ppm (J=14.04 Hz) and 9.77 ppm (J=13.47 Hz), 
each doublet representing one hydrogen. As to why these hydrogens are at such a 
downfield ppm is baffling.  The software used and even experimental spectra of oxindole 
represent these hydrogens as a singlet around 3.5 ppm.  Even with this evidence that 
contradicts the possibility of these hydrogens being represented in this way it is believed 
this is the structure of the product produced.  All the other peaks present in the starting 
material 1H NMR spectrum match up with the peaks shown here.  Also, GC/MS analysis 







Figure 26- 1H NMR spectrum of 1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-2-indolinone 
(72) 
 The 13C NMR of this structure 72 fits what might be expected or predicted more 
closely.  In comparison to the starting material 70 two peaks moved, both upfield.  Most 
notably the peak that had been at 183.0 ppm (labeled f) is shifted to 109.8 ppm, labeled g: 
a good indicator that the product had in fact been reduced.  Other peaks were assigned to 
carbons based on NMR predicting software.  
 







 Given that so much difficulty had been faced earlier when attempting to prepare 
the bromo derivative 59, it was decided to first N-alkylate the benzylidene oxindole 73 
with3-bromo-1-propyne (75) and then “click” with fluoroethylazide (37).  This general 
approach had been accomplished by other groups and, in fact, all the groups that append 
isatin or oxindole with a triazole first N-alkylate with an alkyne.  First, as a model study 
(not shown), isatin (23) was N-alkylated with 3-bromo-1-propyne (75) and the resulting 
product was then “clicked” with FEA.  Evidence that this reaction was successful was 
based on the appearance of the characteristic fluoroethyl triazole peaks in the 1H NMR 
appearing as multiplets between 4.5 and 5.0 ppm, as well as the correct mass peak in the 
LC/MS spectra, however there was also evidence of slight impurities.  This compound 
was not isolated, but it provided evidence that the reaction concept would work.   
 
 
 The N-propargyl benzylidene oxindole 76 was added to DMF and stirred at 50ᵒC 






the mixture and the resulting mixture was stirred for an additional 2 min.  Finally, sodium 
azideand2-fluoroethyltosylate (45) were added and allowed to react with the N-terminal 
alkyne at 80ᵒC for 24 h, yielding 78. 
 The 1H NMR spectrum of compound 78 displayed a number of peaks and may 
show some impurities. Alternatively, the extra peaks may be due to more than one isomer 
or possibly splitting caused by the fluorine. The presence of some product can be 
confirmed because of the peaks between 5.5 ppm and 4.0 ppm which relate to the 
formation of the triazole ring linker.  Clarity and separation of the peaks could be better 
but one can see the three sets of triplets and one singlet representative of the fluoroethyl 
triazole ring that have been observed in many previous 1H NMR spectra of the 
fluoroethyl triazole building blocks. 
 
Figure 28- 1H NMR spectrum of 3-[(p-methoxyphenyl)methylidene]-5-chloro-1-{[1-(2-
fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-one (78) 
 For the next product, 79, the starting material 74 was synthesized and appended 






the click reaction as described above. This molecule was chosen since Kuret’s group at 
Ohio State University determined that 3-(4-dimethylaminobenzylidene) oxindole (74) 
was a good candidate molecule for binding to the tau protein.97 As expressed, one of the 
goals of the present research was to develop a PET imaging agent selective for tau.  
Results showed that 77 was an effective binder to tau protein, Aβ1-42, and α-synuclein 
filaments. Binding to more than one protein in the brain is not ideal in the sense that tau 
selectivity, alone, is desired.  Of the molecules that Kuret identified as selective for tau, 
none were able to cross the BBB.97 Since Ketcha's research group at WSU had been 
working with benzylidene oxindoles in the past for other pharmaceutical purposes, it 
seemed natural for this group to further examine and derivatize74 in attempt to make the 
molecule more selective for tau over Aβ1-42.  Kuret discovered that an iodo group at the 
C-5 position on the benzenoid ring did not affect binding to tau so Knisley, with the 
Ketcha group, produced compounds containing a chloro group at the C-5 position as well 
as a fluoro group. Both derivatives showed enhanced binding to tau. It was determined 
that the chloro group on the benzenoid ring enhanced tau binding the most.152  As a 
result, Cox, also with the Ketcha group, put the chloro group at different positions on the 
benzenoid ring; discovering the chloro at the C-5 position was best for tau binding.  Cox 
also studied the effects of extended conjugation at the C-3 site.  Finally, Cox showed that 
N-alkylation of 74 with a methyl group did not affect binding affinity. This discovery 
opened up the option to put a reporter group at the N-position so this molecule could be 
used as a PET imaging agent for Alzheimer's Disease.153 Lock, also in Ketcha's group, 
attached a fluoroethyl group at the N-position as a reporter group.154 This molecule will 






exploring how to introduce a reporter group at the N-position while modifying the 
lipophilicity. Using click chemistry to introduce a triazole ring to this position would 
effectively alter lipophilicity and provide another way to introduce the reporter group.123  
The triazole ring would also add a third ring moiety.  This has the potential to be 
beneficial to increasing this molecule’s specific binding to tau since the molecules that 
are known to bind to tau selectively have at least three aromatic ring regions connected 
by two rotatable bonds.97 
 The 1H NMR spectrum of compound 79 shows another derivative of benzylidene 
oxindole being first N-alkylated with propargyl bromide 75 and then clicked with 
fluoroethyl azide 37.  The doublet at 8.41 ppm (J=7.37 Hz) represents the carbon labeled 
e.  The splitting is due to the neighboring hydrogen at the ortho position.  The singlet and 
doublet that integrate to 1H at 7.88 ppm, labeled i, describe the E/Z isomer possibility of 
the vinylic hydrogen. The peak at 7.67 ppm represents the protons labeled j and 
seemingly appears to be a doublet of doublets which also suggests a mixture of E/Z 
isomers.  The peak at 7.50 ppm that looks as if it is a triplet, labeled g, is associated with 
the proton with the same label and the splitting is due to the two ortho hydrogens f and h.  
The multiplet of peaks between 7.25 ppm and 6.92 ppm is in the aromatic region and 
represents 3H; which are labeled f, h, and c.  The final peak in the aromatic region is a 
multiplet at 6.75 ppm which represents the hydrogens labeled k.  The peaks between 5.14 
and 4.50 ppm are indicative of the formation of the triazole ring and elimination of the 
alkyne.  Finally, the peak at 3.09 ppm, labeled l, is representative of the six equivalent 







Figure 29- 1H NMR spectrum of 3-{[p-(dimethylamino)phenyl]methylidene}-1-{[1-(2-
fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-one (79) 
 In hindsight the compounds 78 and 79 should have been prepared in EtOH/H2O 
as a solvent instead of DMF since EtOH/H2O is much easier to remove from a product.  
The solvent used in the click reactions to produce the primary building blocks 49 and 51 
was EtOH/H2O so it would have made sense to perform the click reaction of 37 to 78 and 
79 in the same solvent.  Additionally, it would not have mattered if the starting materials 
for 78 and 79 were totally soluble in EtOH/H2O based on evidence that a click reaction 
will take place even in the event that all of the starting materials are not soluble.163,164 As 
the saying goes, hindsight is 20:20.  
The following salts were produced mainly as possible AChE inhibitors.  AChE has been 
implicated into the complex web that is the development of AD.  As mentioned in the 
Introduction section four of the five drugs that are available to help with symptoms of 






approved AChE inhibitor which is able to cross the BBB.  Recently, indolinone-based 
inhibitors of acetylcholinesterase were developed based on the structural resemblance to 
Donepezil hydrochloride. Many of the compounds synthesized were superior to 
Donepezil hydrochloride, especially the 2-chlorobenzyl derivative 79b.155 Given this 
level of AChE inhibitory activity exhibited by these benzylidene oxindoles, it was 
decided to create a triazolyl analog, first to examine the efficacy of this fragment towards 
AChE but also to possibly create an imaging agent for AChE in the case of a fluoroethyl 
derivative. To initiate a program towards these goals, the surrogate building block 49 was 
used to create a quaternary nitrogen of a 3-pyridyl substituted oxindole (e.g., 80). 
  
 To that end, building block 49 was simply added to a solution of 80 in acetonitrile 








 The 1H NMR spectra (DMSO-d6) of compound 81 confirms its structure.  The 
peak at 11.0 ppm, labeled m, is indicative of the proton attached at the N-1 position as 
seen in other spectra of compounds with the proton.  The doublet at 9.18 ppm labeled f 
(JH-H=6.96 Hz) represents the protons on the benzyl ring close to the quaternary carbon. 
The splitting is caused by the protons that are ortho, labeled e which are represented at 
8.68 ppm as a doublet (3JH-H=6.82 Hz) also. The vinylic proton is represented at 8.43 ppm 
as a singlet. Peak h, at 8.09 ppm is attributed to proton on the triazole ring.  The doublet 
at 7.92 ppm, labeled c, is due to the proton at the C-4 position of the oxindole backbone, 
splitting is caused by the meta proton at the C-6 position.  At 7.42-7.33 ppm there is a 
multiplet that represents the protons labeled a, j, k, and l. The doublet at 6.88 ppm (JH-
H=8.38 Hz) represents the proton at the C-6 position.  Finally the singlet labeled g at 5.97 
ppm and the singlet at 5.65 ppm labeled i represent the hydrogens of the two CH2 groups.  







Figure 30- 1H NMR spectrum of 3-({1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-
pyridyl}methylidene)-5-chloro-1H- indol-2-one (81) 
 The 13C NMR of displays peaks labeled m and p which are indicative of the 
carbons associated with the CH2 groups of the molecule.  The peaks between 149.9 ppm 
and 112.1 ppm are in the aromatic region and represent the 17 unique aromatic carbons.  









Figure 31- 13C NMR spectrum of 3-({1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-
pyridyl}methylidene)-5-chloro-1H- indol-2-one (81) 
 For eventual comparison purposes, the 5-chloro version of the previously 
determined optimal derivative bearing a 2-chlorobenzyl capping group was also 
synthesized. Thus, compound 83 was likewise made by reaction of 80 with 2-
chlorobenzyl chloride (82).  Compound 83 incorporates the 2-chlorobenzyl fragment 
which is effective for Ache inhibition, however it is also possible that such quaternization 
might not adversely affect caspase-3 inhibition and such molecules make serve as a dual 
function drug.155 
 
 The 1H NMR spectrum of compound 83 indicated that in fact the product was 
formed however impurities may be present.  The peak at 11.20 ppm, labeled l, represents 
the hydrogen on the nitrogen.  The doublet of doublets at 9.24 ppm (JH-H=6.80 Hz) 
represents the two equivalent hydrogens on the pyridine ring closest to the nitrogen.  
Splitting is due to the hydrogens at the ortho position and the fact that E and Z isomers 
are present.  The doublets at 8.76 ppm and 8.44 ppm, both labeled e, are associated with 
the other two hydrogens on the pyridine ring furthest from the N.  These peaks could be 






hydrogens (JH-H=6.69 Hz) and the presence of the E and Z isomers.  The split singlet at 
8.18 and 7.73 ppm, labeled d is due to the E and Z isomers also.  Each peak represents 
0.5H and together represent the vinylic proton d.  The multiplet at 7.65-7.21 ppm 
represents 6H.  Those six hydrogens are all associated with an aromatic ring, they are 
labeled a, b, h, k, i, and j.  Next, another multiplet labeled c, represents the hydrogen 
next to the chlorine on the lower 6 member ring.  The tiny peak in the middle is not 
counted as a peak (an impurity), the peaks are considered a doublet of doublets, with 
splitting indicative of interaction with hydrogens e and d. The final peak at 6.07 ppm, 
labeled g, is considered a multiplet because of the uneven splitting (J=13.5 Hz).  This 
splitting does not match with any other splitting patterned in the molecule.  Since the CH2 
group is the last moiety to be assigned, this peak is assumed to correspond with those 
protons. 
 
Figure 32- 1H NMR spectrum of 3-({1-[(o-chlorophenyl)methyl]-4-






 The 13C NMR spectrum of compound 83 has the appropriate number of peaks at 
the appropriate chemical shifts to lead to the conclusion that the product was in fact 
formed.  The carbon labeled g appears furthest downfield at as it should since it is part of 
an amide moiety. 
 
Figure 33- 13C NMR spectrum of 3-({1-[(o-chlorophenyl)methyl]-4-
pyridyl}methylidene)-1H- indol-2-one (83) 
 Following the theme of dual function drugs, it was decided to create molecules 
containing a fragment demonstrated to lower Aβ such as a 2,4,6- or 3,4,5-trimethoxy 
fragment with a fragment possibly capable of acting towards GSAP. To the end, the 
known molecule 85 was prepared via an aldol condensation between oxindole 24 and the 
trimethoxybenzyaldehyde 84.  It was envisioned that once appended at the N-position, 
this species would be a potential multitarget drug as well.  This is not a novel compound, 
but as detailed in the multitarget drug section of the introduction, it is useful for cdk-5 
inhibition and it was envisioned that appending a 2,6-difluorobenzyl “fragment” at the N-







 The 1H NMR of compound 85 shows the expected and appropriate peaks.  At 10.6 
ppm a singlet labeled l, represents the proton bonded to the nitrogen.  Another singlet at 
8.02 ppm, labeled f, represents the two hydrogens, also labeled f, on the trimethoxy 
benzene.  The vinylic hydrogen is represented next as a singlet at 7.76 ppm.  The doublet 
furthest downfield, labeled a, represents the proton closest to the nitrogen on the 
oxindole. Splitting of this peak (JH-H=7.37 Hz) is due the hydrogen present at the ortho 
position. The triplets of doublets, at 7.20 ppm (JH-H=7.62, 0.95 Hz) and 6.99 ppm (JH-
H=7.57, 0.86 Hz) represent the protons labeled b and c respectively.  The triplet splitting 
is caused by ortho protons whereas the doublet splitting is caused by each having a 
proton that is meta.  The final doublet at 6.85 ppm, labeled d, represents the final proton 
on the oxindole. Splitting, once again, is due to the ortho interaction (JH-H=7.60 Hz) with 
the neighboring hydrogen.  The singlet at 3.85 ppm, labeled g, represents six hydrogens 
and is associated with the six equivalent hydrogens of the trimethoxy moiety. The final 
singlet at 3.75 ppm, integrated to three protons, represents the other three hydrogens of 







Figure 34- 1H NMR spectrum of 3-[(3,4,5-trimethoxyphenyl)methylidene]-1H- indol-2-
one (85) 
 The 13C NMR of compound 85 shows 15 peaks as expected.  The peak at 167.7 
ppm is definitely the carbon labeled n.  The peaks from 152.7 ppm and 109.8 ppm were 
assigned based on an internet program that predicts the location of each carbon based on 
the structure.  Additionally a DEPT90 of this product was used to determine which peaks 
were C-H peaks.  The peaks at 137.8, 129.1, 121.5, 119.8, 110.6, 109.8 ppm were C-H 
peaks and assigned accordingly.  The peak labeled m at 60.6 ppm, and the peak labeled k 







Figure 35- 13C NMR spectrum of 3-[(3,4,5-trimethoxyphenyl)methylidene]-1H- indol-2-
one (85) 
 The final molecule synthesized was also envisioned as a possible multitarget drug.  
The isatin starting material 86 was reduced to 87 with hydrazine in order to allow for an 
aldol reaction with the trimethoxybenzaldehyde 84 resulting in composite compound 88.  
The trimethoxy group has been linked to lowering the Aβ burden in the AD brain as 
demonstrated by Greengard in 2007 with compound 21which incorporates the same 
2,4,6-trimethoxy benzylidene group as used in this molecule.  The difluoro moiety was 
also used because of results that support its value in creating an effective caspase 







 The 1H NMR of compound 88 provides structural evidence that the product was 
in fact produced.  The singlet e, at 7.52 ppm represents the vinylic photon.  The multiplet 
at 7.47-7.37 ppm, represents the proton labeled k.  The triplet of doublets at 7.20 ppm, 
labeled a, represents the proton at the C-7 position.  It is split by the neighboring proton, 
b, but also is effected by the fluorine atoms that are in close proximity. The triplet at 7.11 
ppm represents the protons at the C-5 and C-6 positions.  The multiplet represented at 
6.93-6.85 ppm labeled j, d is associated with protons on the difluoro benzyl moiety as 
well as the proton at the C-4 position.  The singlet at 6.37 ppm represents the two 
equivalent protons each on the ring of the trimethyl benzyl group.  The singlet at 5.03 
ppm labeled i represents the alkyl protons and finally the peaks at 3.87 ppm h and 3.75 







Figure 36- 1H NMR spectrum of 3-[(2,4,6-trimethoxyphenyl)methylidene]-1-[(2,6-
difluorophenyl)methyl]-1H- indol-2-one (88) 
 The original goals of this research were to provide a proof of concept synthetic 
basis for the so-called Proxy PET concept developed at WSU. To that end, families of 
triazolyl linking building blocks containing either a cold fluoroethyl reporter group as 
well as the more easily accessible benzyl substituted surrogate group were prepared and 
attached to potential targeting agents based on either the isatin or oxindole scaffolds. 
Although conversion of the progenitor alcohol building blocks to the corresponding 
tosylate building blocks could not be achieved, N-alkylation of the analogous bromo 
building block was demonstrated as well as aldolization of an aldehyde building block. 
Additionally, a new class of building blocks were demonstrated wherein a primary 
building block was attached to an isatin, whereupon reduction to the corresponding 
oxindole creates building block which might be diversified by subsequent aldolization 







General. Melting points were determined via the use of open capillaries with an Electro 
thermal melting point apparatus. The 1H and 13C NMR data were obtained on a Bruker 
Avance 300 MHz NMR in either CDCl3or DMSO-d6 solution. Chemical shifts for proton 
NMR are reported in δ (ppm) downfield from tetramethylsilane and 13C NMR shifts are 
calibrated on the DMSO-d6 resonance at 39.50 ppm or the CDCl3 resonance at 77.16 
ppm. Coupling constants (J) are in Hz. The following abbreviations are used to describe 
peak patterns where appropriate: s, singlet; d, doublet; dd, double doublet; t, triplet; q, 
quartet; dt, doublet of triplet; m, multiplet. GC/MS measurements were performed using 
Hewlett-Packard 6890 Series GC with auto injection and mass fragments are reported a 
mass per charge, m/z. The GC was coupled with a mass spectrometer with Hewlett-
Packard 5973 mass selective detector/quadrupole system. Flash column (Silica Gel, 
Premium Rf, 200-400 mesh, Sorbent Technologies) and thin layer chromatography 
reactions were performed on silica gel with indicated solvent systems. 
2-Fluoroethyl tosylate (45)  
To a 50 mL vial charged with dichloromethane (25 mL) and a magnetic stir bar was 
added p-toluenesulfonyl chloride (11.7 mmol, 2.234 g), triethylamine (5.4 mL, 39.025 
mmol),  and 4-dimethylaminopyridine (0.0639 g, 0.523 mmol) while chilling in an ice 
bath for 5 min.  2-Fluoroethanol was then added drop wise over 15 min.   After stirring at 
rt for 20 h the reaction was vacuum filtered and rinsed with hexanes.  The solid was 
discarded and the filtrate was evaporated under reduced pressure.  The resulting oil was 






(GCMS/TLC) was collected as a yellow oil (134 mg, 5.13%); Rf=0.72 (EtOAc): 1H NMR 
(300 MHz, CDCl3) δ 7.84-7.80 (m, 2H), 7.39-7.36 (m, 2H), 4.68-4.65 (m, 1H), 4.52-4.49 
(m, 1H), 4.34-4.31 (m, 1H), 2.47 (s, 3H); 13C NMR (75MHz, CDCl3) δ 145.1, 129.9, 
127.9, 80.55 (d, J=173.5, 1C), 68.43 (d, J=21.23, 1C), 21.64ppm;  GCMS (m/z) 218 
(M+1) 91 (100%). 
1-Benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole (49)  
To a 10 mL vial charged with EtOH/H2O (1:1v/v, 6 mL) and a magnetic stir bar was 
added benzyl bromide (360 µL, 3.03mmol), sodium azide (220 mg, 3.38 mmol), 
triethylamine (40 µL, 0.28 mmol), CuSO4*5H2O (78.0 mg, 10mol%), sodium ascorbate 
(112.7 mg, 20mol%) and propargyl alcohol (200 µL, 3.44 mmol). The reaction vessel 
was capped and heated at 70 ºC for 3.5 h.  H2O (10 mL) was added to the mixture.  The 
product was extracted from the water layer with EtOAc (3 x 20 mL). The organic layer 
was dried using Na2SO4, filtered and evaporated under reduced pressure to afford a pure 
(LC/MS, TLC) off-white solid (527 mg, 92.3%) after allowed to sit overnight: mp 71-74 
ºC (lit.131mp 76-77 ºC; Rf = 0.26 (EtOAc): 1H NMR (300 MHz DMSO) δ 8.04 (s, 1H), 
7.37 - 7.32 (m, 5H), 5.59 (s, 2H), 5.24 (s, 1H), 4.55 (s, 2H); 13C NMR (75 MHz, DMSO) 
δ148.9, 136.6, 129.2, 128.5, 128.4, 123.3, 55.5, 53.2ppm; LCMS190 (M+1) 
 [1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methanol (51)  
To a 10 mL vial charged with EtOH/H2O (1:1v/v 6 mL) and a magnetic stir bar was 
added 2-fluoroethyl tosylate (500 µL, 2.95 mmol), sodium azide (0.3285 g, 5.05 mmol), 
and triethylamine (20 µL, 5 mol%).  The reaction vessel was capped and heated at 60ᵒC 






sulfate pentahydrate (79.7 mg, 10 mol%), and sodium ascorbate (0.1145 g, 20 mol%) 
were added and the mixture was heated at 60ᵒC for an additional 24 h. After cooling to rt, 
H2O (8 mL) was added to the reaction vial and the reaction was vacuum filtered. The 
water layer was extracted with EtOAc (3x 15 mL) and the combined organic layers were 
evaporated under reduced pressure to afford pure (GCMS/TLC) product as a tan oil. The 
aqueous layer was then saturated with Na2SO4 and extracted with EtOAc to provide 
additional product as a tan oil (0.1585 g, 60.48%): Rf = 0.75 (MeOH) 1H NMR (300 MHz 
CDCl3) δ 7.68 (s, 1H), 4.87 (t, J=4.84, J= 75.72, 1H), 4.79 (s, 2H), 4.71 (t, J=4.4, 2H), 
4.62 (t, J=4.84, J=75.72, 1H), 2.98 (s, 2H); 13C NMR (75MHz, CDCl3) δ 148.1, 122.8, 
81.5 (d, J=177.9, 1C), 56.2, 50.5 (d, J= 20.5, 1C); GCMS (m/z) 145 (M+), 54 (100%). 
1-Benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52)  
To a 20 mL vial charged with DCE (7 mL) and a magnetic stir bar was added 1-benzyl-4-
(hydroxymethyl)-1H-1,2,3-triazole (49) (190 mg, 1 mmol) and MnO2 (267 mg, 3 mmol). 
The reaction mixture was stirred at 80 ºC for 4 h and vacuum filtered through a pad of 
zeolite. The pad was washed with DCE (3x 10 mL) and the filtrate evaporated under 
vacuum using rotary evaporation to afford a pure (GC-MS / TLC) off-white solid (136.1 
mg, 72.8%): mp 79-82 ºC (lit.13mp89-90 ºC; Rf = 0.70 (EtOAc): 1H NMR (300 MHz,  
DMSO) δ; 10.03 (s, 1H), 8.98 (s, 1H), 7.39-7.35 (m, 5H), 5.71 (s, 2H);  13C NMR (75 
MHz CDCl3) δ 185.4, 147.5, 135.8, 129.3, 128.8, 128.7, 128.6, 53.7ppm; GC-MS (m/z) 
187 (M+) 91 (100). 






To a 10 mL round-bottom flask charged with DCM (10 mL) and a magnetic stir bar was 
added 1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole (49) (1.006 g, 5.3 mmol) and PBr3 
(1.5 mL, 16 mmol). The reaction mixture was stirred at rt for 4 h, quenched with H2O (2 
mL) and extracted with DCM (3 x15 mL). The combined organic layers were dried using  
anhydrous Na2SO4, filtered and evaporated under reduced pressure to afford a pure (LC-
MS/TLC) white solid (1.0216 g, 75.9%): mp 124-126 ºC; Rf = 0.74 (EtOAc): 1H NMR 
(300 MHz CDCl3);δ 7.51 (s, 1H), 7.42-7.37 (m, 3H), 7.31-7.27 (m, 2H),   5.52 (s, 2H), 
4.55 (s, 2H) 13C NMR (75 MHz CDCl3) δ; 144.9, 134.2,129.2, 128.2, 122.7, 54.3, 
21.6ppm;LC MS (m/z) 254 (M+1). 
1-Benzyl-1H-1,2,3-triazole-4-carboxylic acid (56)  
To a vial charged with EtOH/H2O (1:1v/v, 10 mL) and a magnetic stir bar was added 
benzyl bromide (340 µL, 2.82 mmol)and sodium azide (190 mg, 2.90 mmol). The 
reaction mixture was allowed to stir at 60 ºC for 14 h, after which time the remaining 
reagents CuSO4*5H2O (40.9 mg, 0.15 mmol), sodium ascorbate (59.9 mg, 0.29 mmol) 
and propiolic acid (200 µL 3 mmol) were added. The reaction mixture was allowed to stir 
at 60 ºC for 24h, after which time H2O (1 mL) was added to the mixture and allowed to 
cool in an ice bath.  Aqueous NaOH (10%, 3mL) was added to the mixture and then 
vacuum filtered. Concentrated HCl was then added to the filtrate until the mixture 
reached pH 2. Product was extracted from the filtrate with EtOAc (3 x15 mL) and the 
combined organic layers were dried with anhydrous Na2SO4, filtered and evaporated 
under reduced pressure to afford a pure (TLC) white solid. (471.8 mg, 80.4%): mp 159-






1H), 7.40-7.28 (m, 6H), 5.65 (s, 2H): 13C NMR (75 MHz CDCl3); δ 136.0, 129.4, 129.3, 
129.2, 128.7, 128.5, 128.3, 53.5 (d, J=34.6Hz, 1C)ppm. 
1-(2-Fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde  (58)   
To a 10mL vial charged with dichloroethane (7 mL) and a magnetic stir bar was added 
[1-(2-fluoro-ethyl)-1H-[1,2,3]triazol-4-yl]-methanol (51), (0.1410 g, 0.9719 mmol)and 
activated MnO2 (0.237 g, 2.73 mmol).  The reaction vessel was capped and heated at 
80°C for 18 h.  The reaction mixture was vacuum filtered over zeolite and washed with 
DCE (3 x 10 mL). The solvent was evaporated under reduced pressure to afford the pure 
off-white solid (0.1177 g, 84.66%): mp 70-72ᵒC; Rf = 0.64 (MeOH);  1H-NMR 
(300MHz, CDCl3)  δ: 10.11 (s, 1H), 8.27 (s, 1H),  4.91 (m, 1H), 4.77 (m, 3H); 13C NMR 
(75MHz, CDCl3) δ: 184.8, 147.9, 126.5, 81.0 (d, J=173.2, 1C), 50.9 (d, J=20.4, 1C); 
GCMS (m/z): 143 (M+), 60 (100%); Anal. Calcd for C5H6FN3O2: C, 41.96; H, 4.23; N, 
29.36  Found:  C, 41.72; H, 4.14; N, 29.00 
3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-5-chloro-1H-indol-2-one 
(67)  
To a 10mL vial charged with EtOH (4 mL) and a magnetic stir bar was added 5-chloro-2-
oxindole (171.8 mg, 1.0 mmol), piperidine (0.147 equiv, 16 µL), and 1-(2-fluoroethyl)-
1H-1,2,3-triazole-4-carbaldehyde (58) (121.4 mg, 0.8 mmol).   The mixture was allowed 
to stir for 3 h at 80ᵒC at which time the temperature was decreased to 60ᵒC for an 
additional 2 h.  The mixture was then allowed to cool to rt and placed in the freezer 
overnight. The mixture was vacuum filtered and rinsed with EtOH (10 mL) affording 






ºC; 1H NMR (300 MHz, DMSO-d6) δ 10.8 (d, J=36.15, 1H), 9.45, 8.78 (s, 0.25H, 0.75H) 
, 9.16, 7.99 (d, J=2.25, 0.75H, 0.25H),  8.06, 7.62 (s, 0.25H, 0.75H),  7.30 (ddd, J=19.22, 
8.29, 2.17, 1H), 6.88 (ddd, J=9.64, 8.30, 0.37, 1H), 4.99-4.9 (m, 2H), 4.82 (s, 1H); 13C 
NMR (75MHz, CDCl3) δ: 169.4, 142.8, 141.9, 130.9, 129.9, 126.5, 125.8, 125.6, 123.6, 
123.2, 111.3, 81.1, 51.3 (d, J=19.26, 1H) ppm; MS (m/z) 293 (M++1).   Anal. Calcd for 
C13H10 ClFN4O: C, 53.34; H, 3.44; N, 19.14; Found: C, 53.38; H, 3.29; N, 18.92. 
 3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-1H-indol-2-one (66) 
To a 10mL vial charged with EtOH (4 mL) and a magnetic stir bar was added oxindole 
(0.152g 1.0mmol), piperidine (0.147 equiv, 20 µL), and 1-(2-Fluoroethyl)-1H-1,2,3-
triazole-4-carbaldehyde (58) (0.1657 g, 1.2 mmol).   The mixture was allowed to stir for 
5h at 70ᵒC.  The mixture was then allowed to cool to rt and placed in the freezer 
overnight. The mixture was vacuum filtered and rinsed with cold EtOH (10 mL) 
affording afford a pure (LC/MS, TLC ) solid (0.2601 g, 88.3%): Rf = 0.59 (EtOAc);  mp 
236-241ºC; 1H NMR (300 MHz DMSO-d6) δ 10.73 (s, 1H), 9.44 (s, 1H),7.90 (s, 1H), 
7.80 (d, J=7.51, 1H), 7.23 (t, J=7.61, 1H), 6.99 (t, J=7.52, 1H), 6.87 (d, J=7.72, 1H), 4.94 
(dq, J=6.64, 3.40, 2H), 4.81 (dq, J=6.67, 3.44, 2H); 13C NMR (75MHz, DMSO- d6) δ 
167.8, 142.5, 141.3, 129.6, 129.2, 125.9, 124.3, 121.7, 120.7, 110.0, 82.4 (J=171.3), 
50.67 (J=24.75) ppm; LC/MS (m/z) 259 (M++1) Anal. Calcd for C13H10FN4O: C, 60.46; 
H, 4.29; N, 21.69; Found: C, 60.49; H, 4.29; N, 21.70. 
3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-1-[(2,6-






To a rbf charged with acetonitrile (10 mL) and a magnetic stir bar was added 
KF/Alumina (745.1 mg, 5.36 mmol), and 3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-
yl]methylidene}-1H-indol-2-one (199.7mg, 0.9mmol).  The mixture was stirred for 5 min 
at rt  2-(Bromomethyl)-1,3-difluorobenzene (293.7mg, 1.6mmol) was added and mixture 
was reflux for 18 h in which time all the acetonitrile evaporated but reaction was not lost. 
The sample was redissolved in acetonitrile and vacuum filtered and washed with hot 
acetone.  The filtrate was evaporated under reduced pressure to afford a bright yellow 
solid that was purified via recrystallization (EtOH) to yield product as bright yellow 
crystals (72.6mg, 24.4%): Rf = 0.68 (EtOAC); mp 196-200ºC;  1H NMR (300 MHz 
CDCl3) δ 9.58 (s, 1H), 7.92 (dd, J=46.91, 0.62, 1H), 7.63 (m, 1H), 7.25 (m, 2H), 7.09 (m, 
1H), 6.91 (m, 3H), 5.12 (s, 2H), 4.97 (dt, J= 8.74, 4.48, 1H), 4.81 (quintet,J=4.73, 2H), 
4.74 (q, J=4.03, 1H); 13C NMR (75MHz, CDCl3) δ165.9, 163.3, 143.0, 141.0, 129.9, 
129.2, 124.4, 123.4, 122.2, 119.4, 111.8, 111.4, 108.5, 82.3, 79.9, 50.5, 31.8ppm; LCMS 
(m/z) 385.1 (M+1).  
1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole-2,3-dione (70)  
To a solution of isatin (0.1869 g, 1.3 mmol), in acetonitrile (11 mL) was added 6 equiv of 
KF/alumina (1.09 g, 6.7 mmol) and the resulting mixture was stirred at rt for 5 min after 
which time 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53) was then added to the 
stirred solution and the mixture was refluxed for 24 h.  The mixture was then allowed to 
cool to rt and the suspended KF/alumina was removed by vacuum filtration.  The filtrate 
was evaporated under reduced pressure to afford a sticky orange solid.  Recrystallization 
from EtOH afforded the pure (LC/MS / TLC) product as yellow crystals (0.1472g, 






DMSO-d6): 7.58-7.56 (m, 3H), 7.31-7.24 (m, 6H), 7.11 (td, J =7.54, J =0.73 1H), 5.49 (s, 
2H) 4.99 (s, 2H);  13C NMR (75MHz, CDCl3) δ: 183.0, 157.9, 150.2, 142.1, 138.6, 134.0, 
129.2, 128.9, 128.2, 125.3, 124.0, 122.8, 117.5, 111.5, 54.4, 35.4 ppm; MS (m/z) 318 (M+ 
+1). 
1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-2-indolinone (72) 
To a rbf charged with hydrazine hydrate 80% (8 mL) and a magnetic stir bar was added 
1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole-2,3-dione (70) (0.79 mmol, 0.2515 
g).  The reaction mixture was reflux for 4 h.  The reaction mixture was added to beaker in 
an ice bath.  Aqueous HCl (3M) was added until a pH of 4 was attained and the mixture 
was allowed to stand overnight.  The mixture was vacuum filtered to afford the pure 
(LC/MS, TLC) product as  golden crystals (188.8 mg, 78.6%):  Rf = 0.61 (EtOAc): 
mp190-194ᵒC; 1H NMR (300 MHz DMSO-d6) δ 10.53 (d, J=14.04, 1H), 9.77 (d, 
J=13.47, 1H), 8.14 (s, 1H), 7.40 (ddd, J= 7.45, 1.24, 0.61, 1H), 7.38-7.34 (m, 1H), 7.33-
7.30 (m, 2H), 7.26 (dd, J=7.60, 1.91, 2H), 7.19 (ddd, J=7.88, 7.46, 1.29, 1H),  5.54 (s, 
2H), 4.99 (s, 2H); 13C NMR (75MHz, DMSO- d6) δ160.8, 142.9, 139.2, 136.4, 129.2, 
128.6, 128.3, 127.3, 125.5, 123.9, 122.5, 121.9, 117.7, 109.8, 53.2, 34.5 ppm; LC/MS 
(m/z) 305 (M+ +1) 
 3-[(p-Methoxyphenyl)methylidene]-5-chloro-1-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-
4-yl]methyl}-1H-indol-2-one (78) 
To a 10mL vial charged with N,N-dimethylformamide (5 mL) and a magnetic stir bar was 
added 2-fluoroethyltosylate (1 equiv, 0.0648 g,0.224 mmol), and sodium azide (1.1 






copper (II) sulfate pentahydrate (9.4 mg, 10 mol%) and sodium ascorbate (12.4 mg, 20 
mol%) were added to the mixture turning the solution reddish/brown.  The mixture was 
stirred for 1-2 min in which time the solution changed back to a clear color.  3-[(p-
Methoxyphenyl)methylidene]-5-chloro-1-(2-propynyl)-1H- indol-2-one (76) (1 equiv., 
0.0708 g, 0.219 mmol) was added to the mixture and the whole was heated at 80 ºC for 
24 h.  The reaction was cooled in an ice bath and transferred to a beaker with 30 mL cold 
water after which 10% NH4OH (5 mL) was added to the reaction with stirring.  The 
reaction mixture was then vacuum filtered and then extracted with DCM (40 mL). The 
organic layer was evaporated under reduced pressure to afford the desired product as a 
pure (LC/MS, TLC) greenish solid (0.0424 g, 46.9%): mp 159-162ºC; Rf =0.53; 1H NMR 
(300 MHz DMSO-d6) δ 8.63-6.97 (m, 9H), 5.11 (s, 2H), 4.53 (dt, J=107.63, 40.98, 4H), 
3.85 (d, 3H); 13C NMR  (75 MHz, DMSO-d6)δ 167.3, 161.6, 151.5, 142.6, 141.8, 139.5, 
135.4, 132.2, 130.7, 128.0, 126.6, 123.9, 122.7, 114.9, 114.4, 113.8, 111.4, 55.9, 
35.3ppm; LC/MS (m/z) 413 (M+1). 
3-{[p-(Dimethylamino)phenyl]methylidene}-1-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methyl}-1H-indol-2-one (79)  
To a 10mL vial charged with dimethylformamide (5 mL) and a magnetic stir bar was 
added 2-fluoroethyltosylate (1 equiv, 0.0502 g,0.224 mmol), and sodium azide (1.1 
equiv, 0.0228 g, 0.25 mmol).  The mixture was heated for 30min at 50 ºC.  After 30 min, 
copper (II) sulfate pentahydrate (8.7 mg, 10 mol%) and sodium ascorbate (12.8 mg, 20 
mol%) were added to the mixture turning the solution reddish/brown.  The mixture was 
stirred for 1-2 min. in which time the solution changed back to a clear color. 3-{[p-






0.1046g, 0.219mmol) was added to the mixture and heated at 80 ºC for 24 h.  The 
reaction was cooled in an ice bath and transferred to a beaker with 30 mL cold water after 
which 10% NH4OH (5 mL) was added to the reaction with stirring.  The reaction mixture 
was then extracted with DCM (3x 15 mL). The combined organic layers were evaporated 
under reduced pressure to afford product as a red oil (LC/MS, TLC). Recrystallization 
(DCM/Hexanes) was attempted and was not successful.  The DCM/Hexanes were 
evaporated under reduced pressure to obtain the oil once again which was added to two 
other samples (LJM-2-83 and LJM-2-85) and was purified via silica gel chromatography 
(EtOAc/Hexanes  40:60 and flushed with MeOH), to afford  pure product (LC/MS, TLC) 
as orange/red crystals (0.1668g, 47.6%): Rf = 0.48 (EtOAc);  mp 110-115 ºC; 1H NMR 
(300 MHz DMSO-d6) δ 8.41 (d, J=7.37, 1H), 7.93-7.83 (m, 1H), 7.68 (dd, J=7.26, 4.50, 
2H), 7.51-7.48(m, 1H), 7.25-6.92(m, 3H), 6.75 (td, J=4.48, 2.63, 2H), 5.14 (d, J= 3.65, 
2H), 4.83 (q, J=4.36, 1H), 4.66 (dq, J=10.36, 5.03, 2H), 4.55 (q, J=4.86, 1H), 3.09 (s, 
6H)ppm; LC/MS (m/z) 319 (M++1). 
3-({1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-pyridyl}methylidene)-5-chloro-1H-
indol-2-one (81)   
To a rbf charged with acetonitrile (5 mL) and a magnetic stir bar was added 1-benzyl-4-
(bromomethyl)-1H-1,2,3-triazole (53) (135.6mg, 0.54mmol), and 3-[(4-
pyridyl)methylidene]-5-chloro-1H-indol-2-one (80) (101.5mg, 0.43mmol).  The reaction 
was refluxed for 1 h then transferred to a vial (10 mL) where it was heated for 23 h at 
60ᵒC.  The solution was allowed to cool to rt then vacuum filtered and washed with 






v/v) .  A pure (LC/MS) dark purple solid (0.0810 g, 43.9%) was collected by vacuum 
filtration and washed with cold EtOH:  mp 248-250ᵒC;  1H NMR (300 MHz DMSO-d6) δ 
11.0 (s, 1H), 9.18 (d, J=6.96, 2H), 8.68 (d, J=6.82, 2H), 8.43 (s, 1H), 8.09 (s, 1H), 7.92 (s, 
1H), 7.42-7.33 (m, 6H), 6.88 (d, J=8.38, 1H), 5.97 (s, 2H), 5.65 (s, 2H)ppm.  LC/MS 
(m/z) 430 (M+ +1);  13C NMR (75MHz, DMSO- d6) δ 166.5, 149.9, 144.9, 141.9, 140.6, 
136.0, 134.8, 131.7, 130.8, 129.3, 129.1, 128.8, 128.6, 126.5, 125.8, 125.4, 122.4, 112.1, 
55.1, 53.5 ppm; Anal. Calcd for C24H19 ClFN5O+: C, 54.72; H, 4.02; N, 12.83; Found: C, 
54.81; H, 3.76; N, 12.83. 
 3-({1-[(o-Chlorophenyl)methyl]-4-pyridyl}methylidene)-1H-indol-2-one (83)  
To a 20mL vial charged with acetonitrile (8 mL) and a magnetic stir bar was added 3-[(4-
pyridyl)methylidene]-5-chloro-1H-indol-2-one (80) (209.4 mg, 0.9 mmol), and 2-
chlorobenzyl chloride (160 µL, 1.5 mmol).  The mixture was stirred at 60ᵒC for 23 h after 
which time the reaction was cooled to rt, vacuum filtered, and washed with hexanes (10 
mL). The resulting solid was purified via recrystallization (EtOH:H2O, 1:1) to afford the 
pure product (LC/MS, TLC) as black crystals (211.2 mg, 56.9%):Rf = 0.00 (EtOAC); mp 
155-160 ºC;1H NMR (300 MHz DMSO-d6) δ 11.20 (s, 1H), 9.22 (dd, J=20.15, 6.80, 2H), 
8.76 (d, J=6.86, 1H), 8.44 (d, J=6.51, 1H), 8.18, 7.73 (s, 0.5H, 0.5H), 7.65-7.21 (m, 6H), 
6.95 (m, 1H), 6.07 (d, J=13.46, 2H);13C NMR (75MHz, DMSO-d6) δ146.1, 145.2, 132.2, 
131.9, 131.7, 130.8, 130.7, 130.5, 129.2, 128.6, 128.2, 124.0, 123.6, 122.4, 112.7, 112.2, 







To a 10 mL vial charged with EtOH (5 mL) and a magnetic stir bar was added isatin 
(158.1 mg, 1.1 mmol), 3,4,5-trimethoxybenzaldehyde (259.8 mg, 1.3 mmol) and 
piperidine (0.147 equiv, 20 µL).  The reaction was stirred at 70ᵒC for 6 h, allowed to cool 
to rt and then placed in the freezer overnight to crystallize.  The product was collected via 
vacuum filtration.  Pure product (LC/MS, TLC) was obtained as a yellow powder (211.2 
mg, 56.9%): Rf =0.56 (EtOAC); mp 194-196 ºC;1H NMR (300 MHz DMSO-d6) δ 10.6 (s, 
1H), 8.02 (s, 2H), 7.76 (s, 1H). 7.67 (d, J= 7.37, 1H), 7.20 (td, J=7.62, 0.95, 1H), 6.99 
(td, J=7.57, 0.86, 1H), 6.85 (d, J=7.60, 1H), 3.85 (s, 6H), 3.75 (s, 3H);13C NMR (75MHz, 
CDCl3) δ 167.7, 152.7, 140.9, 140.2, 137.8, 130.0, 129.1, 125.6, 121.5, 119.8, 110.6, 
109.8, 60.6, 56.3ppm; LCMS (m/z) 312 (M+1). 
3-[(2,4,6-Trimethoxyphenyl)methylidene]-1-[(2,6-difluorophenyl)methyl]-1H-indol-2-one 
(88) 
To a 15 mL vial charged with EtOH (5 mL) and a magnetic stir bar was added 1-[(2,6-
difluorophenyl)methyl]-2-indolinone (87) (250.2 mg, 1 mmol), 2,4,6-
trimethoxybenzaldehyde (259.8 mg, 1.3 mmol) and piperidine (0.147 equiv, 20 µL).  The 
reaction was stirred at 70ᵒC for 48 h at which time it was cooled to rt and put in the 
freezer for 48 h to crystallize.  Product was collected via vacuum filtration. 
Recrystallization with EtOH was performed on the solid to obtain the pure product 
(GCMS/TLC) as yellow crystals (145 mg, 34.4%).  Rf=0.50 (60:40 EtOAc: Hexanes) 1H 
NMR (300 MHz DMSO-d6) δ 7.52 (s, 1H), 7.47-7.37 (m, 1H), 7.20 (td, J=7.26, 2.24, 
1H), 7.11 (t, J=8.15, 2H), 6.93-6.85 (m, 3H), 6.37 (s, 2H), 5.03 (s, 2H), 3.87 (s, 3H), 3.75 
(s, 6H); 13C NMR (75MHz, DMSO-d6) δ 167.5, 163.45-163.04 (m, 1H), 159.8-159.6 (m, 






J=7.53, 1H), 112.1 (d, J=7.57, 1H), 108.2, 105.0, 91.3, 32.2, 19.0; GCMS (m/z) 437.1 









1. Alzheimer, A. Uber eineeigenartie Erkankung der Hirnrinde. Allg. Z. 
Psychiatr.1907, 64, 146. 
2. Hippius, H.; Neundӧrfer, G. The discovery of Alzheimer’s disease.  Dialogues in 
Clin. Neurosci. 2003, 5, 101-108. 
3. 2014 Alzheimer's Disease Facts and Figures. Alzheimer's and Dementia. 2014, 10, 
47-92 
4. Hyman, B.T.; Phelps, C.H.; Beach, T.G.;Bigio, E.H.; Cairns, N.J.; Carrillo, 
M.C.;Dickson, D.W.; Duyckaerts, C.; Frosh, M.P.; Masliah, E.; Mirra, S.S.; 
Nelson, P.T.; Schneider, J.A.; Thal, D.R.; Thies, B.; Trojanowski, J.Q.; Vinters, 
H.V.; Montine, T.J. National Institute on Aging–Alzheimer’s Association 
guidelines on neuropathologic assessment of Alzheimer’s disease. 
AlzheimersDemen. 2012, 8, 1–13. 
5. Goedert, M.; Spillantini, M.G.; A Century of Alzheimer's Disease.  Science. 2006, 
314, 777-781. 
6. Life expectancy in 2006 in the United States. 
http://data.worldbank.org/indicator/SP.DYN.LE00.IN/countries/US--
XS?display=graph 
7. Life expectancy in 1906 in the United States. 
https://www.census.gov/statab/hist/HS-16.pdf 
8. Hirtz, D.; Thurman, D.J.; Gwinn-Hardy, K.; Mohamed, M.; Chaudhuri, A.R.; 
Zalutsky, R.  How common are the "common" neurologic disorders?  Neurology 
2007, 68, 326-337. 
9. Schneider, J.A.; Arvanitakis, Z.; Bang, W.; Bennett, D.A.  Mixed brain 
pathologies account for most dementia cases in community-dwelling older 
persons.  Neurology 2007, 69, 2197-2204. 
10. Jellinger, K.A.; Attems, J.  Neuropathological evaluation of mixed dementia. J. 
Neurol. Sci. 2007, 257, 80-87. 







12. Ronch, J.L. Mourning and Grief in late life Alzheimer's dementia: Revisiting the 
vanishing self.  Am. J.Alzheimers Dis. 1996, 11(4), 25-28. 
13. Hardy, J.A.; Higgins, G.A.  Alzheimer’s disease: The amyloid cascade 
hypothesis.  Science 1992, 256, 184-185. 
14. Querfurth, H.W.; LaFerla, F.M.  Alzheimer’s disease.  N. Engl. J. Med.  2010, 
362, 329-344. 
15. Haass, C.; Selkoe, D.J.  Soluble protein oligomers in neurodegeneration:  lessons 
from the Alzheimer’s amyloid β-peptide.  Nat. Rev. Mol. Cell Biol.  2007, 8, 101-
112. 
16. Lichtenthaler, S.F.; Wang, R.; Grimm, H.; Uljon, S.N.; Masters, C.L.; Beyreuther, 
K. Mechanism of the cleavage specificity of Alzheimer’s disease γ-secretase 
identified by phenylalanine-scanning mutagenesis of the transmembrane domain 
of the amyloid precursor protein.Proc. Natl. Acad. Sci. USA 1999, 96, 3053-3058 
17. Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T.  
Neurofibrillary tangles but not senile plaques parallel duration and severity of 
Alzheimer’s disease.  Neurology 1992, 42, 631-639. 
18. Sadeghi-Nejad, N.  The lessons of failure:  What we can learn from 
bapineuzuinab’s blowup.  Forbes (Pharma & Healthcare) August 7, 2012. 
19. Therapeutics. Flurizan. http://www.alzforum.org/therapeutics/flurizantm 
20. Therapeutics. Semagacestat. http://www.alzforum.org/therapeutics/semagacestat 
21. Weggen, S.; Erikson, J.L.; Sagi, S.A., Pietrzil, C.U.; Ozols, V.; Fauq, A.; Golde, 
T.E., Koo, E.H. Evidence that nonsteroidal anti-inflammatory drugs decrease 
amyloid beta 42 production by direct modulation of gamma-secretase activity.  J. 
Biol. Chem.  2003, 278, 31831-31837. 
22. Winblad, B.; Giacobini, E.; Frolich, L.; Friedhoff, L.T., Bruinsma, G.; Becker, 
R.E.; Greig, N.H. Pherserine efficacy in Alzheimer’s disease.  J. Alzheimer’s Dis.  
2010, 22, 1201-1208. 
23. Therapeutics. Bapineuzumab. 
http://www.alzforum.org/therapeutics/bapineuzumab 
24. Therapeutics. Solanezumab. http://www.alzforum.org/therapeutics/solanezumab 
25. Cramer, P.E. et al. ApoE-directed therapeutics rapidly clear beta-amyloid and 






26. Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-
like pathology in the PDAPP mouse. Nature 1999, 400, 173–177. 
27. Dodart, J.C. et al. Immunization reverses memory deficits without reducing brain 
Aβ burden in Alzheimer’s disease model. Nat. Neurosci. 2002, 5, 452–457. 
28. Holmes, C. et al. Long-term effects of Aβ42 immunisation in Alzheimer’s 
disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 
372, 216–223. 
29. Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate 
Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 322–333. 
30. Doody, R.S. et al. Phase 3 trials of solanezumab for mild-to-moderate 
Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 311–321. 
31. Vellas, B. et al. Designing drug trials for Alzheimer’s disease: what we have 
learned from the release of the phase III antibody trials: a report from the 
EU/US/CTAD Task Force. Alzheimers Dement. 2013, 9, 438–444. 
32. Lue, L.F.; Kuo, Y.M.; Roher, A.E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; 
Kurth, J.H.; Rydel, R.E.; Rogers, J.  Soluble amyloid β peptide concentration as a 
predictor of synaptic change in Alzheimer’s disease.  Am. J.Pathol.  1999, 155, 
853-862. 
33. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes.  
Acta.Neuropathol.  1991, 82, 239-259. 
34. Hardy J. Alzheimer’s disease:  The present situation and our tasks.  Neurobiol 
Aging.  1994, 15, S111-S112. 
35. Lindsley, C.W. Alzheimer’s Disease:  Development of Disease-Modifying 
Treatments Is the Challenge for Our Generation.ACS Chem. Neurosci. 2012, 3, 
804-805. 
36. Forman, M.S.; Trojanowski, J.Q.; Lee, V.M-Y.  Neurodegenerative diseases:  a 
decade of discoveries paves the way for therapeutic breakthroughs.  Nature 
Medicine.  2004, 10, 1055-1063. 
37. Trojanowski, J.Q.;  Lee, V.M-Y.  The Alzheimer’s brain.  American Journal of 
Pathology.  2005, 167, 1183-1188. 
38. Skovronsky, D.M.; Lee, V. M-Y.; Trojanowski, J.Q.  Neurodegenerative diseases:  
New concepts of pathogenesis and their therapeutic implications.  Annu Rev 






39. Mohandas, E.; Rajmohan, V.; Raghunath, B. Neurobiology of Alzheimer’s 
disease. Indian J. Psychiatry 2009, 51, 55-61. 
40. Maccioni, R.B.; Farias, G.; Morales, I.; Navarrete, L. The revitalized tau 
hypothesis on Alzheimer’s diseaseArch MedRes.  2010, 41, 226-231.  
41. Lee, V. M-Y.; Trojanowski, J.Q.  The disordered neuronal cytoskeleton in 
Alzheimer’s disease.  CurrOpinNeurobiol.  1992, 2, 653-656. 
42. Kosik, K.S.; Joachim, C.L.; Selkoe, D.J.  Microtubule-associated protein tau (tau) 
is a major antigenic component of paired helical filaments in Alzheimer disease.  
Proc. Natl. Acad. Sci. USA.  1986, 83, 4044-4048. 
43. Braak, H.; Braak, E.  Neuropathological staging of Alzheimer-related changes.  
ActaNeuropathol.  1991, 82, 239-259. 
44. Duyckaerts, C.; Hauw, J.J.  Prevalence, incidence and duration of Braak’s stages 
in the general population:  can we know? Neurobiol Aging.  1997, 18, 389-392.  
45. Morsch, R.; Simon, W.; Coleman, P.D.  Neurons may live for decades with 
neurofibrillary tangles. J NeuropatholExp Neurol.  1999, 58, 188-197. 
46. Bierer, L.M.; Hof, P.R.; Purohit, D.P.; Carlin, L.; Schmeidler, J.; Davis, K.L.; 
Perl, D.P.  Neocortical neurofibrillary tangles correlate with dementia severity in 
Alzheimer’s disease. Arch Neurol. 1995, 52, 81-88. 
47. Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.;  Hyman, B.T.  
Neurofibrillary tangles but not senile plaques parallel duration and severity of 
Alzheimer’s disease.  Neurology 1992, 42, 631-639. 
48. Maccioni, R.B.; Lavados, M.; Guillón, M.; Mujica, C.; Bosch, R.; Farías, G.; 
Fuentes, P. Anomalously phosphorylated tau and Abeta fragments in the CSF 
correlates with cognative impairment in MCI subjects.  Neurobiol Aging.  2006, 
27, 237-244. 
49. Masliah, E.; Mallory, M.; Hansen, L.; DeTeresa, R.; Terry, R.D. Quantitative 
synaptic alterations in the human neocortex during normal aging.  Neurology 
1993, 43, 192-197. 
50. Kaduszkiewicz, H.; Zimmermann, T.; Beck-Bornholdt, H-P.; van den Bussche, H.  
Cholinesterase inhibitors for patients with Alzheimer’s disease:  systematic 









53. Danysz, W.; Parsons, C.G.  The NMDA receptor antagonist memantine as a 
symptomatological and neuroprotective treatment for Alzheimer’s disease:  
preclinical evidence.  Int J Geriatr Psychiatry.  2003, 18, S23-32. 
54. Chen, F.; Hasegawa, H.; Schmitt-Ulms, G.; Kawarai, T.; Bohm, C.; Katayama, 
T.; Gu, Y.; Sanjo, N.; Glista, M.; Rogaeva, E.; Wakutani, Y.; Pardossi-Piquard, 
R.; Ruan, X.; Tandon, A.; Checler, F.; Marambaud, P.; Hansen, K.; Westaway, 
D.; St George-Hyslop, P.; Fraser, P.  TMP21 is a presenilin complex component 
that modulates gamma-secretase but not epsilon-secretase activity.Nature.  2006, 
440, 1208-1212. 
55. Fraering, P.C.; Ye, W.; LaVoie, M.J.; Ostaszewski, B.L.; Selkoe, D.J.; Wolfe, 
M.S. Gamma-secretase substrate selectivity can be modulated directly via 
interaction with a nucleotide-binding site. J Biol Chem.  2005, 51, 41987-41996.   
56. Netzer, W.J.; Dou, F.; Cai, D.; Veach, D.; Jean, S.; Li, Y.; Bornmann, W.G.; 
Clackson, B.; Xu, H.; Greengard, P.  Gleevec inhibits β-amyloid production but 
not notch cleavage.  Proc. Natl. Acad. Sci. USA 2003, 100, 12444-12449. 
57. Eriksen, J.L.; Sagi, S.A.; Smith, T.E.; Weggen, S.; Das, P.; McLendon, D.C.; 
Ozols, V.V.; Jessing, K.W.; Zavitz, K.H.; Koo, E.H.; Golde, T.E. NSAIDs and 
enantiomers of flurbiprofen target ɣ-secretase and lower Aβ42 in vivo.  J Clin 
Invest 2003, 112, 440-449. 
58. Lleó, A.; Berezovska, O.; Herl, L.; Raju, S.; Deng, A.; Bacskai, B.J.; Frosch, 
M.P.; Irizarry, M.; Hyman, B.T.  Nonsteroidal anti-inflammatory drugs lower 
Aβ42 and change presenilin 1 conformation.  Nat Med.  2004, 10, 1065-1066. 
59. Ohno, M.; Chang, L.; Tseng, W.; Oakley, H.; Citron, M.; Klein, W.L.; Vassar, R.; 
Disterhoft, J.F.  Temporal memory deficits in Alzheimer’s mouse models: rescue 
by genetic deletion of BACE1.  Eur J Neurosci.  2006, 23, 251-260. 
60. Esler, W.P.; Wolfe, M.S.  A portrait of Alzheimer secretases--new features and 
familiar faces.  Science 2001, 293, 1449-1454. 
61. Roberson, E.D.; Mucke, L. 100 years and counting:  Prospects for defeating 
Alzheimer’s disease. Science 2006, 314, 781–784. doi:10.1126/science.1132813. 
62. Gervais, F.; Paquette, J.; Morissette, C.; Krzywkowski, M.Y.; Azzi, M.; Lacombe, 
D.; Kong, X.; Aman, A.; Laurin, J.; Szarek, W.A.; Tremblay, P.  Targeting 
soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis.  






63. Therapeutics. Alzhemed. http://www.alzforum.org/therapeutics/alzhemedtm 
64. Rolland, Y.; Van Kan, G.A.; Vellas, B.  Physical activity and Alzheimer’s 
disease:  From prevention to therapeutic perspectives.  J Am Med Dir Assoc.  
2008, 9, 390-405. 
65. Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L.  
A Potential Role of the Curry Spice Curcumin in Alzheimer's Disease.  Curr. 
Alzheimer Res.  2005, 2, 131-136. 
66. Paddock, C. Scientists discover big clue to how caffeine wards off Alzheimer's. 
Medical News Today. 2014. 
http://www.medicalnewstoday.com/articles/275181.php 
67. Arendash, G.W.  Caffeine Reverses Cognitive Impairment and Decreases Brain 
Amyloid-β Levels in Aged Alzheimer's Disease Mice.  J Alzheimers Dis. 2009, 
17, 661-680. 
68. Kung, H.F. “The β-Amyloid Hypothesis in Alzheimer’s Disease:  Seeing Is 
Believing.”  ACS Med. Chem. Lett. 2012, 3, 265-267. 
69. Jeffery, S. FDA approves thrid amyloid PET tracer for Alzheimer’s. Medscape. 
Mar 21, 2014. http://www.medscape.com/viewarticle/822370 
70. Mathis, C.A.; Wang, Y.; Klunk, W.E. Imaging β-amyloid plaques and 
neurofibrillary tangles in the aging Human Brain.  Curr Pharm Design 2004, 10, 
1469-1492. 
71. Zimmer, E.R.; Leuzy, A.; Gauthier, S.; Rosa-Neto, P.  Developments in tau PET 
imaging.  Can J Neurol Sci. 2014, 41, 547-553. 
72. Shoghi-Jadid, K.; Small, G.W.; Agdeppa, E.D.; Kepe, V.; Ercoli, L.M.; Siddarth, 
P.; Read, S.; Satyamurthy, N.; Petric, A.; Huang, S-C.; Barrio, J.  Localization of 
neurofibrillary tangles and beta-amyloid plaques in the brains of living patients 
with Alzheimer disease.  Am J GeriatrPsychiatr.  2002, 10, 24-35. 
73. Villemagne, V.L.; Furumoto, S.; Fodero-Tavoletti, M.T.; Mulligan, R.S.; Hodges, 
J.; Harada, R.; Yates, P.; Piguet, O.; Pejoska, S.; Doré, V.; Yanai, K.; Masters, 
C.L.; Kudo, Y.; Rowe, C.C.; Okamura, N.  In vivo evaluation of a novel tau 







74. Maruyama, M.; Shimada, H.; Suhara, T.; Shinotoh, H.; Ji, B.; Maeda, J.; et al. 
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients 
compared to normal controls.  Neuron 2013, 79, 1094-1108. 
75. Chien, D.T.; Bahri, S.; Szardenings, A.K.; Walsh, J.C.; Mu, F.; Su, M.Y.; 
Shankle, W.R.; Elizarov, A.; Kolb, H.C. Early clinical PET imaging results with 
the novel PHF-tau radioligand [F-18]-T807.  J Alzheimers Dis.  2013, 34, 457-
468. 
76. Okamura, N.; Furumoto, S.; Fodero-Tavoletti, M.T.; Mulligan, R.S.; Harada, R.; 
Yates, P.; et al.  Non-invasive assessment of Alzheimer’s disease neurofibrillary 
pathology using 18F-THK5105 PET.  Brain 2014, 137, 1762-1771. 
77. Iqbal, K.; Grundke-Iqbal, I. Alzheimer disease is multifactorial and 
heterogeneous.  Neurobiol Aging 2000, 21, 901-902. 
78. Zhang, H-Y. One-compound-multiple-targets strategy to combat Alzheimer’s 
disease. FEBS Letters 2005, 579, 5260-5264. 
79. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, 
M.; Melchiorre, C.  Multi-target-directed ligands to combat neurodegenerative 
diseases.  J. Med. Chem. 2008, 51, 347-372. 
80. León, R.; Garcia, A.G.; Marco-Contelles, J.  Recent advances in the multitarget-
directed ligands approach for the treatment of Alzheimer’s disease.  Med Res Rev.  
2013, 33, 139-189. 
81. Sabbagh, M.N.  Drug development for Alzheimer’s disease:  Where are we now 
and where are we headed?  Am. J. Geriatr. Pharmacother.  2009, 7, 167-185. 
82. Cavalli, A.; Bolognesi, M.L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, 
E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C.  A small molecule targeting the 
multifactorial nature of Alzheimer’s Disease.  Angew. Chem. Int. Ed.  2007, 46, 
3689-3692. 
83. Bolognesi, M.L.;  Cavalli, A.; Melchiorre, C.  Memoquin:  A multi-target-directed 
ligand as an innovative therapautic opportunity for Alzheimer’s disease.  
Neurotherapeutics.  2009, 6, 152-162. 
84. Mariano, M.  Schmitt, C.; Miralinaghi, P.; Catto, M.; Hartmann, R. W.; Carotti, 
A.; Engel, M.  First selective dual inhibitors of tau phosphorylation and beta-
amyloid aggregation, two major pathogenic mechanisms in Alzheimer’s disease.  






85. Anighoro, A.; Bajorath, J.; Rastelli, G.  Polypharmacology:  Challenges and 
oportunities in drug discovery.  J. Med. Chem.  2014, 57, 7874-7887. 
86. Flajolet, M.; He, G.; Heiman, M.; Lin, A.; Nairn, A.C.; Greengard, P.  Regulation 
of Alzheimer’s disease amyloid-β formation by casein kinase 1.  Proc Natl 
AcadSci USA.  2007, 104, 4159-4164. 
87. Hӧttecke, N.; Liebeck, M.; Baumann, K.; Schubenel, R.; Winkler, E.; Steiner, H.; 
Schmidt, B.  Inhibition of ɣ-secretase by the CK1 inhibitor IC261 does not 
depend on CK1δ.  Bioorg Med Chem Lett. 2010, 20, 2958-2963. 
88. He, G.; Luo, W.; Li, P.; Remmers, C.; Netzer, W.; Hendrick, J.; Bettayeb, K.; 
Flajolet, M.; Gorelick, F.; Wennogle, L.P.; Greengard, P.  Gamma-secretase 
activating protein, a therapautic target for Alzheimer’s disease.  Nature 2010, 467, 
95-98. 
89. Stadelmann, C.; Deckwerth, T.L.; Srinivasan, A.; Bancher, C.; Bruck, W.; 
Jellinger, K.; Lassmann, H.  Activation of caspase-3 in single neurons and 
autophagic granules of granulovacuolar degeneration in Alzheimer’s Disease:  
Evidence for apoptotic cell death.  Am J Pathol.  1999, 155, 1459-1466. 
90. Chu, J.; Li, J. G.; Joshi, Y. B.; Giannopoulos, P. F.; Hoffman, N. E.;Madesh, M.; 
Pratico, D. Gamma secretase-activating protein Is a substrate for caspase-3: 
implications for Alzheimer’s disease.  Biol Psychiatry. 2015, 77, 720-728. 
91. Joshi, G.; Wang, Y.  Golgi defects enhance APP amyloidogenic procession in 
Alzheimer’s Disease.  Bioessays 2015, 37, 240-247. 
92. Johnson, K.; Liu, L.; Majdzadeh, N.; Chavez, C.; Chin, P.C.; Morrison, B.; Wang, 
L.; Park, J.; Chugh, P.; Chen, H.M.; D’Mello, S.R. Inhibition of neuronal 
apoptosis by the cyclin-dependent kinase inhibitor GW8510:  Identification of 3’ 
substituted indolones as a scaffold for the development of neuroprotective drugs.  
J. Neurochem. 2005, 93, 538-548. 
93. Ishiguro K.; Takamatsu M.; Tomizawa K.;  Tomizawa K.; Omori, A.; Takahashi 
M.; Arioka M.; Uchida T.; Imahori, K. Tau protein kinase I converts normal tau 
protein into A68 like component of paired helical filaments, J. Biol. Chem. 1992, 
267, 10897–10901. 
94. Baloyannis, S.J.  Golgi apparatus and protein trafficking in Alzheimer’s disease.  






95. De Sa Alves, F.R.; Barreiro, E.J.; FragaManssour, C.A. “From nature to drug 
discovery: the indole scaffold as a ‘privileged structure’.” Mini-Rev. Med. Chem. 
2009, 9, 782-793 
96. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, 
W. L.; Lundell,  G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; Lotti, V.J.; 
Cerino, D.J.; Chen, T.B.; Kling, P.J.; Kunkel, K.A.; Springer, J.P.; Hirshfield, J. 
Methods for drug discovery: development of potent, selective, orally effective 
cholecystokinin antagonistsJ. Med. Chem. 1988, 31, 2235-2246 
97. Honson, N.S.; Johnson, R.L.; Huang, W.; Inglese, J.; Austin, C.P.; Kuret, J. 
Differentiating Alzheimer disease-associated aggregates with small molecules. 
Neurobiol Dis. 2007, 28, 251-260. 
98. Cohen, P. “Protein Kinases the Major Drug Targets of the Twenty First Century?” 
Nature Rev,. Drug Discov. 2002, 1, 309-315; b) Prakash, C.R.; Theivendren, P.; 
Raja, S. “Indolin-2-ones in clinical trials as potential kinase inhibitors: a review.” 
Pharmacology & Pharmacy 2012, 3, 62-71; c) Noble, M.E.M.; Endicott, J.A.; 
Johnson, L.N. “Protein kinase inhibitors: insights into drug design from structure” 
Science 2004, 303, 1800-1805. 
99. Chu, W.; Zhang, J.; Zeng, C.; Rothfuss, J.; Tu, Z.; Chu, Y.; Reichert, D.; Welch, 
M.J.; Mach, R.H. N-benzylisatin sulfonamide analogues as potent caspase-3 
inhibitors:  Synthesis in vitro activity and molecular modeling studies.  J.Med. 
Chem. 2005, 48, 7637-7647. 
100. Jiang, Y.; Hansen, T.V.  Isatin 1,2,3-triazoles as potent inhibitors against caspase-
3. Bioorg Med Chem Lett.  2011, 21, 1626-1629. 
101. Chu, W.; Rothfuss, J.; Zhou, D.; Mach, R.H.  Synthesis and evaluation of isatin 
analogs as caspase-3 inhibitors:  Introduction of a hydrophilic group increases 
potency in a whole cell assay.  Bioorg Med Chem Lett.  2011, 21, 2192-2197. 
102. Zhang, W.; Oya, S.; Kung, M.P.; Hou, C.; Maier, D.L.; Kung, H.F.  F-18 
Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in 
the brain. Nuc Med and Bio.  2005, 32, 799-809. 
103. Glaser, M.; Arstad, E. "Click Labeling" with 2-[18F]Fluoroethylazide for Positron 
Emission Tomography. Bioconjugate Chem.  2007, 18, 989-993. 
104. Ono, M.; Watanabe, R.; Kawashima, H.; Cheng, Y.; Kimura, H.; Watanabe, H.; 






emission tomography probes for in Vivo imaging of β-amyloid plaques in 
Alzheimer’s disease.  J. Med. Chem.  2009, 52, 6394-6401.  
105. Stephenson, K.A.; Chandra, R.; Zhuang, Z.; Hou, C.; Oya, S.; Kung, M.; Kung, 
H.K.  Fluoro-pegylated (FPEG) Imaging Agents Targeting Aβ Aggregates.  
Bioconjugate Chem.  2007, 18, 238-246. 
106. Ametamey, S.M., Honer, M.; Schubiger, P.A.  Molecular Imaging with PET. 
Chem Rev.  2008, 108, 1501-1516.  
107. Marik, J.; Sutcliffe, J.L. Click for PET:  rapid preparation of [18F]fluoropeptides 
using CuI catalyzed 1,3-dipolar cycloaddition.  Tetrahedron Lett.  2006, 47, 6681-
6684. 
108. Nguyen, Q.D.; Challapalli, A.; Smith, G.; Fortt, R.; Aboagye, E.O.  Imaging 
apoptosis with positron emission tomography:  ‘Bench to bedside’ development 
of the caspase-3/7 specific radiotracer [18F]ICMT-11.  European Journal of 
Cancer.  2012, 48, 432-440. 
109. Jia, L.; Cheng, Z.; Shi, L.; Li, J.; Wang, C.; Jiang, D.; Zhou, W.; Meng, H.; Qi, 
Y.; Cheng, D.; Zhang, L.  Fluorine-18 labeling by click chemistry: Multiple 
probes in one pot.  Appl. Radiat. Isotopes 2013, 79, 64-70. 
110. Glaser, M.; Robins, E.G.  Click labeling in PET radiochemistry.  J Label 
CompdRadiopharm.  2009, 52, 407-414. 
111. Wang, M.; Yuan, Y.; Liang, G.  “Click chemistry” for molecular imaging.  
Current Molecular Imaging.  2012, 1. 
112. Phelps, M.E. Positron Emission Tomography Provides Molecular Imaging of 
Biological Processes. Proc Nat Acad Sci. 2000, 97, 9226-9233. D.O.I.: 
10.1073/pnas.97.16.9226. 
113. Gillings, N.  Radiotracers for Positron Emission Tomography Imaging.  
Magn.Reson. Mater. Phy.  2013, 26, 149-158. 
114. Ametamey, S.M.; Honer, M.; Schubiger, P.A.  Molecular Imaging with PET.  
Chem. Rev.  2008, 108, 1501-1516. 
115. Cherry, S. The 2006 Henry N. Wagner lecture: of mice and men (and positrons)-
advances in PET imaging technology.  J. Nucl. Med. 2006, 47, 1735-1745. 
116. Muller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals:  Looking Beyond 






117. Le Bars, D.  Fluorine-18 and medical imaging:  Radiopharmaceuticals for 
positron emission tomography. J. Fluorine Chem.  2006, 127, 1488-1493. 
118. Meldal, M; Tornoe, C.W. “Cu-Catalyzed azide-alkyne cycloaddition” Chem Rev. 
2008, 108, 2952-3015. 
119. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise Huisgen 
cycloaddition process: copper(I)-catalyzed regioselective  ‘ligation’ of azides and 
terminal alkynes. Angew. Chem. Int. Ed. 2002, 41, 2596-2599. 
120. Tornoe, C.W.; Christensen, C.; Meldal, M.  Peptidotriazoles on solid phase:  
[1,2,3]-triazoles by regiospecific copper(I)-catalysed 1,3-dipolar cycloadditions of 
terminal alkynes to azides.  J. Org. Chem. 2002, 67, 3057-3064. 
121. Moses, J.E.; Moorhouse, A.D.  The growing applications of click chemistry.  
Chem. Soc. Rev.  2007, 36, 1249-1262. 
122. Kolb, H.C.; Sharpless, K.B.  The growing impact of click chemistry on drug 
discovery.  Drug Discov Today.  2003, 8, 1128-1137. 
123. Bock, V.D.; Hiemstra, H.; van Maarseveen, J.H. CuI-catalyzed alkyne-azide 
“click” cycloadditions from a mechanistic and synthetic perspective.  Eur. J. Org. 
Chem. 2006, 2006, 51-68.  
124. Bock, V.D.; Speijer, D.; Hiemstra, H.; Van Maarseveen, J.H.  1,2,3-triazoles as 
peptide bond isosteres:  synthesis and biological evaluation of cyclotetrapeptide 
mimics.  Org.Biomol. Chem.  2007, 5, 971-975. 
125. Hausner, S.H.; Marik, J.; Gagnon, K.J.; Sutcliffe, J.L.  In vivo positron emission 
tomography (PET) imaging with an αvβ6 specific peptide radiolabeled using 18F-
“click” chemistry:  Evaluation and comparision with the corresponding 4-
[18F]Flurorbenzoyl- and 2-[18F]Fluoropropional-peptides.  J Med Chem. 2008, 51, 
5901-5904. 
126. Zhou, D.; Chu, W.; Peng, X.; McConathy, J.; Mach, R.H.; Katzenellenbogen, J.A. 
Facile purification and click labeling with 2-[18F]fluoroethyl azide using solid 
phase extraction cartridges.Tetrahedron Lett. 2015, 56, 952-954. 
127. Smith, G.; Glaser, M.; Nguyen, Q-D.; Shan, B.; Arstad, E.; Aboagye, E.O.  
Design, synthesis, and biological characterization of a caspase 3/7 selective isatin 






128. Shealy, Y. Fulmer, and Charles A. Krauth. (Alkylsulfonyl)methanesulfonates as 
Anticancer Agents. Southern Research Institute, assignee. Patent 4727174. 23 
Feb. 1988. Print. 
129. Parenty, A.D.C; Smith, L.V.; Cronin, L.  An unusual substitution reaction 
directed by an intramolecular re-arrangement.  Tetrahedron.  2005, 61, 8410-8418 
130. Bernard-Gauthier, V.; Aliaga, A.; Aliaga, A.; Boudjemeline, M.; Hopewell, R.; 
Kostikov, A.; Rosa-Neto, P.; Thiel, A.; Schirrmacher, R.  Syntheses and 
evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor 
kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET 
imaging agents. ChemNeurosci.  2015, 6, 260-276. 
131. Sarmiento-Sanchez, J.I.; Ochoa-Teran, A.; Rivero, I.A.  Conventional and 
microwave assisted synthesis of 1,4-disubstituted 1,2,3-triazoles from Huisgen 
cycloaddition. Arkivoc 2011, 4, 177-188. b.) Mukherjee, N.;  Ahammed, 
S.; Bhadra, S.;Ranu, B.  Solvent-free one-pot synthesis of 1,2,3-
triazole derivatives by the ‘Click’ reaction of alkyl halides or aryl boronic 
acids, sodium azide and terminalalkynes over a Cu/Al2O3 surface under ball-
milling.  Green Chem.  2013, 15, 389-397. 
132. Reddy, K.R.; Rajgopal, K.; Kantam, M.L.  Copper(II)-promoted regioselective 
synthesis of 1,4-disubstituted 1,2,3-triazoles in water.  Synlett.  2006, 6, 957-959. 
133. Sharghi, H.; Khalifeh, R.; Doroodmand, M.M.  Copper nanoparticles on charcoal 
for multicomponent catalytic synthesis of 1,2,3-triazole derivatives from benzyl 
halides or alkyl halides, terminal alkynes and sodium azide in water as a “Green” 
solvent.  Adv. Synth.Catal.  2009, 351, 207-218.  
134. Kacprzak, K. Efficient one-pot synthesis of 1,2,3-Triazoles from benzyl and alkyl 
halides.  Synlett.  2005, 6, 943-946. 
135. Gallardo, H.; Conte, G.; Bryk, F.; Lourenco, M.C.S.; Costa, M.S.; Ferreira, V.F. 
Synthesis and evaluation of 1-alkyl-4-phenyl-[1,2,3]-triazole derivatives as 
antimycobacterial agent.  J. Braz. Chem. Soc.  2007, 18, 1285-1291. 
136. Lee, I.; Choe, Y.S.; Choi, J.Y.; Lee, K-H.; Kim, B-T.  Synthesis and evaluation of 
18F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque 
imaging. J. Med. Chem.  2012, 55, 883-892. 
137. Hugenburg, V.; Breyholz, H-J.; Riemann, B.; Hermann, S.; Schober, O.; Schafers, 
M.; Gangadharmath, U.; Mocharla, V.; Kolb, H.; Walsh, J.; Zhang, W.; Kopka, 






on triazole-substituted hydroxamates:  (Radio)synthesis and in Vitro and first in 
vivi evaluation.  J. Med. Chem.  2012, 55, 4714-4727. 
138. Bouhfid, R.; Joly, N.; Massoni, M.; Cecchelli, R.; Lequart, V.; Martin, P.; Essassi, 
E.M.  An efficient synthesis of new spiro[indolo-3(1H),2’(3’H)-oxadiazolyl] and 
1-(triazol-4-ylmethyl) isatin derivatives.  Heterocycles.  2005, 65, 2949-2955. 
139. Tipson, S.  On esters of p-toluenesulfonic acid.  J. Org. Chem.  1944, 9, 235-241. 
140. Kazemi, F.; Massah, A.R.; Javaherian, M.  Chemoselective and scalable 
preparation of alkyl tosylates under solvent-free conditions.  Tetrahedron 2007, 
63, 5083-5087. 
141. Kabalka, G.W.; Varma, M.; Varma, R.S.  Tosylation of alcohols.  J. Org. Chem.  
1986, 51, 2386-2388. 
142. Dobbs, A.P.; Guesne, S.J.J.; Parker, R.J.; Skidmore, J.; Stephenson, R.A.; 
Hursthouse, M.B.  A detailed investigation of the aza-Prins reaction.  Org.Biomol. 
Chem. 2010, 8, 1064-1080.  
143. Bottorff, E. Preparation of nitrobenzyl alcohol mesylates and tosylates.  Lilly Co 
Eli, assignee.  Patent 3745188. 10 Jul. 1973 
144. Ding, R.; He, Y.; Wang, X.; Xu, J.; Chen, Y.; Feng, M.; Qi, C. Treatment of 
alcohols with tosylchoride does not always lead to the formation of tosylates.  
Molecules. 2011, 16, 5665-5673. 
145. Abdallah, H.M. Small molecule caspase inhibitors using isatin and oxindole 
scaffolds and a combinatorial approach.  WSU Master’s Thesis 2010. 
146. Li, X.; Huang, P.; Cui, J.J.;  Zhang, J.; Tang, C. Novel pyrrolyllactone and 
pyrrolyllactamindolinones as potent cyclin-dependent kinase 2 inhibitors. Bioorg. 
Med. Chem. Lett. 2003, 13, 1939-1942. 
147. Zhang, W.; Go, M. L. Functionalized 3-benzylidene- indolin-2-ones: Inducers of 
NAD(P)H-quinone oxidoreductase 1 (NQO1) with antiproliferative activity. 
Bioorg. Med. Chem. 2009, 17, 2077-2090 
148. Coda, A.C.; Invernizzi, A.G.; Righetti, P.P.; Tacconi, G.; Gatti, G. (Z)- and (E)-
Arylidene-1,3-dihydroindol-2-ones: configuration, conformation, and infrared 
carbonyl stretching frequencies.J ChemSocPerkin Trans. II 1984, 4, 615-619. 
149. Yamawaki, J.; Ando, T. Potassium fluoride on inorganic solid supports. A search 
for further efficient reagents promoting hydrogen-bond-assisted alkylationsChem. 






150. Clay C.M. Synthesis of isatin derivatives used for the inhibition of pro-apoptotic 
jurkat t cells. WSU Master’s Thesis 2011 
151. Clay, C.M.; Abdallah, H.M.; Jordan, C.; Knisley, K.; Ketcha, D.M.  N-Alkylation 
of isatins utilizing KF/Alumina.  Arkivoc 2012, 6, 317-325. 
152. Knisley, K.J. Libraries from libraries approach to the synthesis of arylidene 
oxindoles.  WSU Master’s Thesis. 2013. 
153. Cox, K.W. Synthesis and biological activity of indolinones.  WSU Master’s 
Thesis.  2014. 
154. Boyer, A.M.L. Unpublished WSU Master’s Thesis. 2015. 
155. Akrami, H.; Mirjalili, B.F.; Khoobi, M.; Nadri, H.; Moradi, A.; Sakhteman, A.; 
Emami, S.; Foroumadi, A.  Indolinone-based acetylcholinesterase inhibitors:  
Synthesis, bioligical activity and molecular modeling.  Eur. J. Med. Chem.  2014, 
84, 375-381. 
 
